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ABSTRACT 
In this thesis, we explore the density of the microglia in the cerebral and 
cerebellar cortices of individuals with autism to investigate the hypothesis that 
neuroinflammation is involved in autism. We describe in our findings an increase in 
microglial density in two disparate cortical regions, frontal insular cortex and visual 
cortex, in individuals with autism (Tetreault et al., 2012).  Our results imply that there is a 
global increase in the microglial density and neuroinflammation in the cerebral cortex of 
individuals with autism.  
We expanded our cerebellar study to additional neurodevelopmental disorders 
that exhibit similar behaviors to autism spectrum disorder and have known cerebellar 
pathology.  We subsequently found a more than threefold increase in the microglial 
density specific to the molecular layer of the cerebellum, which is the region of the 
Purkinje and parallel fiber synapses, in individuals with autism and Rett syndrome.  
Moreover, we report that not only is there an increase in microglia density in the 
molecular layer, the microglial cell bodies are significantly larger in perimeter and area in 
individuals with autism spectrum disorder and Rett syndrome compared to controls that 
implies that the microglia are activated.  Additionally, an individual with Angelman 
syndrome and the sibling of an individual with autism have microglial densities similar to 
the individuals with autism and Rett syndrome.  By contrast, an individual with Joubert 
syndrome, which is a developmental hypoplasia of the cerebellar vermis, had a normal 
density of microglia, indicating the specific pathology in the cerebellum does not 
	  	   vii	  
necessarily result in increased microglial densities.  We found a significant decrease in 
Purkinje cells specific to the cerebellar vermis in individuals with autism. 
These findings indicate the importance for investigation of the Purkinje synapses 
in autism and that the relationship between the microglia and the synapses is of great 
utility in understanding the pathology in autism. Together, these data provide further 
evidence for the neuroinflammation hypothesis in autism and a basis for future 
investigation of neuroinflammation in autism.  In particular, investigating the function of 
microglia in modifying synaptic connectivity in the cerebellum may provide key insights 
into developing therapeutics in autism spectrum disorder. 
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CHAPTER 1:  INTRODUCTION 
 
Autism Spectrum Disorder 
Autism spectrum disorder is heterogenous clinically and etiologically where the 
diagnosis is entirely based on the behavioral phenotype (Miles et al., 2011). It is a 
neurodevelopmental disorder described by two core features: a lack in social 
communication and restricted repetitive behaviors, often diagnosed by age three. 
(American Psychiatric Association, DSM 5, 2013). The diagnosis of the disorder is at 
present entirely clinical, based on differing aspects of behavior and its developmental 
time course. This includes a number of specifiers (extensions to a diagnosis that further 
clarify its course, severity, or special features). Diagnosis in the clinic can include 
additional disorders such as attention deficit hyperactivity disorder, Rett syndrome, 
seizures, other disorders and neurological symptoms that are comorbid with autism 
(American Psychiatric Association, DSM 5, 2013). Since autism spectrum disorder is a 
heterogeneous disorder, it may involve additional symptoms including seizures, sensory 
abnormalities such as hypersensitivity, motor deficits, and gastrointestinal alterations 
(Danielsson et al., 2005; Leekam et al., 2007; Vilensky et al., 1981; D’Eufemia et al., 
1996; Horvath et al., 1999; De Magistris et al., 2010). Seizures occur in 38% of 
individuals with autism, and the frequency of seizures has great impact on the 
individuals’ lives (Danielsson et al., 2005). Sensory abnormalities have been often 
described in autism spectrum disorder. These include pain insensitivity and 
hypersensitivity to tactile, auditory, and visual stimuli, which can be debilitating 
(Bemporad et al., 1979; Grandin & Scariano, 1986; Cesaroni & Garber, 1991). Over 90% 
of individuals with autism have sensory abnormalities in multiple domains, and that the 
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sensory disabilities are extensive, multimodal and continuous across age and ability in 
individuals with autism (Leekam et al., 2007). In addition, individuals with autism 
experience a number of motor deficits, which may include gait disturbances, various 
postural instabilities, greater clumsiness, and altered motor coordination (Vilensky et al., 
1981; Bauman & Kemper 2005; Molloy et al., 2003). A number of individuals with 
autism experience gastrointestinal disturbances and 43% of individuals with autism in 
one sample had altered intestinal permeability compared to neurotypicals, who had none 
(D’Efufemia et al., 1996).  Of these gastrointestinal disturbances, the most severe 
symptoms include constipation and diarrhea, and constipation is associated with severity 
of the language and social impairment in individuals with autism (Gorrindo et al., 2012; 
Chandler et al., 2013). Emerging evidence of increased autoantibodies may indicate an 
inflammatory state of the intestines and may alter the mucosal barrier and integrity, 
which may lead to gastrointestinal issues in individuals with autism (Coury et al., 2012). 
As of 2012, about 1 in 50 children in the United States have been diagnosed with 
autism or autism spectrum disorder (up from 11 per 1,000 in 2008) (Blumberg et al., 
2013; Rutter et al., 2005). This increase in prevalence has raised tremendous concern 
among parents, clinicians and the scientific community, leading to the suggestion that 
environmental factors may contribute to the epidemic of autism (Miles et al., 2011). 
Currently, the cause of autism remains unknown.  Considerable advances in the genetic 
causes of autism can be attributed to identifying known genetic mutations and disorders 
that predispose to the development of autism (Miles et al., 2011). Approximately 20-25% 
of autism spectrum disorder can be identified by a genetic cause, leaving 75-85% as 
presently unknown causes (Miles et al., 2011). Moreover there are a number of 
 
2
	  
environmental exposures during fetal development that increase the risk of autism that 
include maternal infection and immune activation, elevated metabolic conditions such as 
diabetes and obesity and elevated levels of C reactive protein in the mother’s serum 
(Brown et al., 2004; Patterson et al., 2011; Krakowiak et al, 2012; Brown et al., 2013). It 
is possible that an interaction of genes and environmental exposures contribute to the 
increased incidence in autism. Insights from three areas of study are invaluable for 
understanding the underlying mechanisms of autism: first, examination of autopsy tissue 
of individuals with autism for pathological and genetic analysis; second, patient studies 
investigating behavior and genetics in living individuals with autism; and third, 
investigations using mouse models of autism for both genetic causes of autism and 
environmental contributions to developing autism. Integrating these research areas 
provides promise for better diagnostics, behavioral treatments and therapeutics for 
individuals with autism. 
 
Genetic Studies of Autism 
There is now strong evidence that genetic alterations can contribute strongly to 
the autism phenotype. First, there are data on overall heritability. If one of a pair of 
monozygotic twins has autism, there is an 88% likelihood that the other will have a form 
of autism, whereas if the twins are dizygotic, the chances are 31% that the other twin will 
have autism (Rosenberg et al., 2009). A more recent study by Hallmayer and colleagues 
(2011) describes a 77% concordance for monozygotic male twins with autism spectrum 
disorder and a 31% concordance among male dizygotic pairs, as well as a 50% 
concordance for female monozygotic pairs, and 36% concordance for female dizygotic 
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pairs, and attributes the variance in liability to shared environmental factors and a 
moderate genetic heritability (Hallmayer et al., 2011). Second, single gene disorders, 
referred to as “syndromic autism,” present autism-like features; these include fragile X, 
Rett syndrome, tuberous sclerosis complex, and Timothy syndrome (Miles et al., 2011). 
The genetic causes of autism account for 20-25% of autism cases based on data from 
genome-wide association studies of autism, single gene mutations in autism, and copy 
number variations (CNVs), i.e., chromosomal deletions or duplications (Miles et al., 
2011).  The most common chromosomal abnormalities in autism are found on the 
maternally-derived 15q duplications of the Prader Willi/Angelman region, which 
accounts for 1-3% of cases with autism (Wang et al., 2013).  The most commonly 
implicated gene in this region is UBE3A. Clinically-relevant CNVs were found in eight 
out of 29 individuals with autism (27.5%) using a 1Mb genome-wide array (Jacquemont 
et al., 2006). Sebat and colleagues (2007) described de novo copy number variations in 
10% of children in which they are the sole family member with autism, 2% from autism 
in multiple family members compared to 1% of neurotypicals, implicating de novo 
germline mutation as a substantial risk factor for autism (Sebat et al., 2007). Genes 
encoding neuronal cell-adhesion molecules, including NRXN1, NLGN1 ASTN2, 
CNTN4, were enriched with CNVs in autism, and genes involved in the ubiquitin 
pathways, including UBE3A, PARK2, RFWD2 and FBXO40, were affected by CNVs 
not observed in controls using a whole genome CNV study of 550,000 single nucleotide 
polymorphism markers in 859 individuals with autism and 1,409 neurotypicals (Glessner 
et al., 2009). In some monozygotic twins who are discordant for autism, the UBE3A gene 
is methylated in the autistic twin, which suppresses the expression of the gene (Wang et 
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al., 2013).  To date, the SFARI website (https://gene.sfari.org/autdb/) reports 252 
annotations for CNVs and 582 genes thought to be associated with autism (Basu et al., 
2007) which is 2% of the entire genome.  Thus, multi-genetic alterations, as well as 
genetic and environmental interactions during critical periods of development, may 
contribute to autism.  
Additionally, investigators are studying the genetics in autism by analyzing the 
transcriptome, the set of all mRNA molecules. The number of transcripts and transcript 
abundance for each gene is measured in various tissues and cells to determine genes and 
possible networks of genes that may be dysregulated in autism. Microarray analysis of 
cerebellar tissue, prefrontal cortex and caudate-putamen reveal an increase in transcripts 
related to AMPA-type glutamate receptors in individuals with autism compared to 
neurotypicals (Purcell et al., 2001). Lymphoblastoid cell lines from five male twins 
discordant for autism based on language impairment revealed an increase in transcripts 
for the pro-inflammatory cytokines and a decrease in transcripts for those that are 
involved in brain development, neuronal differentiation and axon guidance in the 
individuals with autism (Hu et al., 2006).  
Lymphoblastoid cell lines genomic profiling in individuals with autism compared 
to controls reveals a small number of genes expressed predominately in natural killer cell 
mediated cytotoxicity (Gregg et al., 2008). These findings indicate that a number of genes 
involved in natural killer cell proliferation are elevated in individuals with autism that can 
contribute to the autism phenotype. Gene expression profile analysis of superior temporal 
gyrus, auditory cortex, shows an increased transcript level of many immune system-
related genes specifically related to T cell mediated acquired immune mechanisms 
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individuals with autism compared to controls (Garbett et al., 2008). Additionally, there is 
a decrease in genes involved in neuronal development and neurite outgrowth in autistic 
cases compared to neurotypicals (Garbett et al., 2008). The expression patterns appear to 
be associated with late recovery of an autoimmune disorder, rather than an innate 
immune response (Garbett et al., 2008). Importantly, this study was limited to a small 
number of individuals with autism (N=6); thus, replication with a larger sample size 
would be useful would be useful for testing the auto-immune hypothesis.   
In a more recent study using microarray analysis of gene expression in individuals 
with autism compared to controls, Voineagu et al. (2011) describe a module of elevated 
immune and microglial genes and deduce that the increased gene expression of the 
immune and microglia genes is a non-genetic etiology since these genes have not been 
found in genome-wide association studies, which points to the genes being causally 
related to autism. This implies that the elevated immune and microglial genes are 
possibly a result of internal or external environmental influences on inflammation in 
autism (Voineagu et al., 2011). These data describe alterations in the expression of genes 
involved in synapse formation and inflammation in the developing brain of individuals 
with autism. Since only 20-25% of the incidence of autism is accounted for by genetics, 
and the etiology is largely unknown, environmental factors likely warrant further 
exploration. In particular, it is not clear how inflammation alters synaptic development 
and how disrupted synaptic development of neural network formations can influence 
inflammatory genes. One explanation advanced by Paul Ashwood and colleagues (2006) 
is that "immune dysregulation could result in the generation of localized or systemic 
inflammation and/or the release of immunomodulatory molecules that could influence, 
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alter, or modify neurodevelopment and/or neuronal function, especially at critical times 
of development."  Specifically, there could be inflammatory events at critical time 
periods during fetal and postnatal development that could alter proper network formation 
and maintenance dysregulating the normal brain development. Since then, substantial 
work has been done that addresses this general set of possibilities as discussed below.  
 
Neuroinflammation in Autism 
There have been numerous reports implicating neuroinflammation or an increase 
in production of microglial cells in the central nervous system in autism spectrum 
disorder (Vargas et al., 2005; Pardo et al., 2005; Zimmerman et al., 2005; Voineagu et al., 
2011; Chez & Guido-Estrada, 2010; Wei et al., 2011; Morgan et al., 2010; Tetreault et 
al., 2012; Suzuki et al., 2013). Neuroinflammation is best described as activated 
microglia and astrocytes and increased production of cytokines such as interleukin-6 (IL-
6) and tumor necrosis factor-alpha (TNF-alpha), which are all measures of an 
inflammatory state (Monnet-Tschudi et al., 2011). 
Vargas and colleagues’ (2005) innovative study of human autopsy tissue reported 
an increase in cytokines in the brains of individuals with autism compared to 
neurotypicals. In addition, individuals with autism have a significant increase in 
cytokines in the cerebral spinal fluid and in the frontal cortex compared to neurotypicals 
(Zimmerman et al., 2005; Vargas et al., 2005; Li et al., 2009). Wei and colleagues (2011) 
found an increase in IL-6 in the cerebellum of individuals with autism and hypothesized 
that the microglia are altering the cerebellar granule cell excitatory synapses (Wei et al., 
2011). There is a significant increase in the area fraction scored positive for an immuno 
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stain for microglia of human leukocyte antigen receptor (HLA-DR) in the cerebellum of 
individuals with autism compared to controls (Vargas et al., 2005). However, this method 
did not measure the microglial cell densities, sizes and shapes. Thus, quantification of 
microglia and shape analysis are essential to studying the state of microglia activation in 
the brains of individuals with autism.  Morgan and colleagues (2010) reported an increase 
in microglia in dorsal lateral prefrontal cortex in individuals with autism and observed 
microglial processes retracting and thickening suggesting the microglia were in an 
activated state. Similarly, we reported an increase in the microglial density in fronto-
insular cortex and visual cortex in individuals with autism. Since these are two disparate 
cortical areas, this indicates a global increase in the microglial density in individuals with 
autism (Tetreault et al., 2012). These data support the hypothesis that neuroinflammation, 
specifically, increased density of microglia, is involved in autism spectrum disorder. Our 
results for molecular and granule cell layers of cerebellar cortex for individuals with 
autism and related disorders compared to neurotyical subjects are reported in Chapter 3 
of this thesis. 
 
Microglia 
Microglia reside throughout the brain and have long been thought to mainly 
comprise the brain’s immune system, which is distinctly separated from the body’s 
immune system by the blood-brain barrier. In the quiescent state, microglia actively 
survey their environment and make contact with synapses (Wake et al., 2009). Microglia 
phagocytose invading microorganisms and debris to defend against infection, clear 
damaged tissue, and dispose of metabolic waste (Graeber & Streit 1990, 2010). 
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Moreover, microglia are essential for normal brain development and are critical for 
synaptic plasticity (Paolicelli et al., 2011; Schafer et al., 2012). 
Microglia arise from cells in the yolk sac in embryogenesis and later in life from 
cells in the bone marrow.   Microglia originate in the yolk sac during embryogenesis and 
can be detected in the brain rudiment from embryonic day eight in mice where microglia 
continually rise steadily during the first two postnatal weeks, when the majority of 
microglia are born (Alliot et al., 1999). More recently, using a tamoxifen-inducible Cre 
recombinase under the control of Runx-1, a hematopoietic transcription factor, confirmed 
that microglia originate from embryonic Runx-1-expressing yolk sac hematopoietic 
progenitors between 7.25 and 7.5 days post-conception (Ginhoux et al., 2010).  
Moreover, the authors reported that in the healthy mouse brain that peripheral myeloid 
cells do not contribute to new microglia to achieve maintenance numbers in the adult 
brain (Ginhoux et al., 2010). Additionally, Kierdorf described the yolk sac progenitors 
that give rise to microglia and identified them as early 8 days post conception (Kierdorf 
et al., 2013). Mouse microglia originated from primitive c-kit+ yolk sac precursors 
developing into CD45+ c-kitlo CX3CR1− cells prior to maturation and migrate into the 
embryonic maturing brain as CD45+ c-kit- CX3CR1+ cells and proliferate into the 
microglia (Kierdorf et al., 2013). These studies provide evidence that the majority of 
adult microglia in the health brain arise during early development.  
To defend against infection, microglia phagocytose invaders, damaged tissue and 
metabolic waste (Graeber & Streit 1990, 2010). It is conceivable that maternal 
inflammation elicits an activation of microglia, which can be a risk factor for autism 
(Patterson, 2009, 2011). In a mouse model of peripheral organ inflammation, cerebral 
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microglia recruit monocytes into the brain through the release of TNF-alpha (D’Mello et 
al., 2009). When microglia are activated by an infection, traumatic brain injury, stroke, or 
neurodegenerative disease, they enter the phagocytic phase, engulfing and removing 
debris in the brain in contrast to the quiescent stage where microglia are primarily 
engaged in surveying their environment (Lin & Bergles, 2004; Wake et al., 2009). 
Microglia appear to have functions separate from immune activity. Increasing 
evidence points to a key role in neurodevelopment and neural plasticity through the 
mechanism of synaptic pruning (Paolicelli et al., 2011; Schafer et al., 2012). 
Visualization of fluorescently labeled microglia in the mouse brain using two-photon 
imaging shows that microglia actively survey their environments by retracting and 
expanding their processes in response to neuronal stimuli (Nimmerjahn et al., 2005; 
Davalous et al., 2005 and Wake et al., 2009). A mouse model of neurodegeneration 
resulting from brain ischemia shows microglia increase contact with synapses that have 
reduced activity (Wake et al., 2009). 
During the peak critical period in postnatal development of the visual system, 
upon visual stimulation microglia contact dendritic spines, synaptic terminals, and clefts 
in layer II and IV of the visual cortex (Tremblay et al., 2010). In the developing visual 
system, microglia are necessary for phagocytic synapse elimination in the mouse retino-
geniculate pathway for normal development, which is dependent on the microglia 
phagocytic signaling pathway of the complement receptor CR/C3, a property of the 
innate immune system (Schaffer et al., 2012).  Together these data exhibit that microglial 
phagocytosis is crucial for normal brain development and circuit formation. As a result of 
these studies, a number of questions arise: Is the neuroinflammation an indicator of 
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dysregulated synaptic connectivity?  Or is the neuroinflammation in response to systemic 
infection?  Or could it be both?  Since autism is a heterogenous disorder, could the 
neuroinflammation represent a dysregualtion in the synaptic connectivity and a systemic 
infection?  Or could it be due to a history of systemic infections? 
 
Maternal Infection in Autism 
There is evidence that maternal viral infection in the first trimester and maternal 
bacterial infection in the second trimester have significant association with autism 
(Atladóttir et al., 2010). Individuals with autism have elevated levels of a number of 
inflammatory cytokines in amniotic fluid compared to neurotypicals (Abdallah et al., 
2011). There is also a significant association between elevated levels of C-reactive 
protein (indicative of the inflammatory response) in maternal serum and the likelihood 
that her child was autistic (Brown et al., 2013). In addition, a subset of people with 
autism have a continuous pro-inflammatory pathology in the brain and cerebral spinal 
fluid, and it is hypothesized that maternal infection or a systemic infection may lead to 
inflammation and autism spectrum disorder (Chez & Guido-Estrada, 2010). Prenatal 
infection and immune dysfunction are biologically plausible potential causes of autism 
(Patterson et al., 2011). Using a mouse model of maternal immune activation (MIA), a 
single injection of interleukin-6 (IL-6) during mouse pregnancy results in offspring with 
behavioral deficits similar to those in autism, including deficiencies in prepulse inhibition 
(PPI) and latent inhibition (LI), but these deficits do not occur when IL-6 is eliminated 
from the MIA model using genetic methods or blocking antibodies (Smith et al., 2007). 
Simultaneous administration of a poly(I:C) and an anti-IL-6 antibody inhibits the PPI, LI, 
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and exploratory and social deficits as well as the alterations in gene expression in the 
brains MIA offspring (Smith et al., 2007). Similarly, MIA in IL-6 knock-out mice do not 
exhibit behavioral deficits as seen in the MIA wild-type offspring (Smith et al., 2007). 
Together these data indicate that the cytokine IL-6 crucial for moderating behavioral and 
transcriptional changes in the MIA mouse model. 
In a mouse model of MIA, polyinosine:cytosine (poly(I:C)) injection elicits a viral 
infection response, where the offspring demonstrate behaviors similar to autism, 
including deficits in social communication and interaction, reduction in ultrasonic 
vocalizations (USVs), and increased stereotyped/repetitive behaviors such as excessive 
marble burying and self-grooming (Malkova et al., 2012; Hsiao et al., 2011). 
Additionally, the MIA offspring exhibit a reduction in the linear density of Purkinje cells 
specific to lobule VII of the cerebellum, which is a hallmark of autism neuropathology, 
indicating that the alteration of the Purkinje cells is induced by maternal activation of the 
immune system occurring during embryonic development (Shi et al., 2009). The MIA 
offspring after a poly(I:C) injection exhibit changes in a number of cytokines in the 
brains and sera in a region and age-specific manner (Garay et al., 2012). The MIA-
induced cytokines do not breach the blood brain barrier, permit immune cell infiltration 
or lead to an increase in microglia (Garay et al., 2012). Although these results argue that 
there is an increased level of cytokines in brain regions similar to those reported in 
autism, there is no elevation in the microglia in this mouse model.   
In another model of maternal inflammation, administering a lipopolysaccharaide 
(LPS) injection and a concurrent single treatment of an IL-1 receptor antagonist results in 
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normal brain development in the mouse, providing promise for treatments that are 
protective for normal fetal brain development (Girard et al., 2010). 
 
Gastrointestinal Abnormalities in Autism 
Gastrointestinal disturbances occur in individuals with autism including 
inflammatory bowel syndrome, reflux esophagitis, chronic gastritis, chronic 
duodenitisdisaccharide malabsorptionmay (Horvath et al., 1999). Again, the question 
arises as to whether it is causative or correlative, relative to the behavioral phenotype that 
defines autism. Based on parent questionnaires and evaluations by pediatric 
gastroenterologists, diagnosis of autism was concordant with a clinical diagnosis of any 
(95%) gastrointestinal disorder, most commonly (85%) constipation, which was 
associated with younger age of onset and increased social impairment (Gorrindo et al., 
2012). Using parent reports, individuals with autism have increased history of vomiting 
and diarrhea and nearly half of the individuals with autism described having an individual 
lifetime gastrointestinal symptom (Chandler et al., 2013). Altered intestinal permeability 
was reported in nine of the 21 (43%) children with autism compared to none of the 40 
neurotypicals, indicating an increased passage of peptides through the gut mucosa in 
individuals with autism (D'Eufemia et al., 1996). It has been hypothesized that 
individuals with autism have a “leaky gut,” or high intestinal permeability, that is caused 
by a disruption in the tight junctions of the gut that have their origin during infancy 
(D'Eufemia et al., 1996; De Magistris et al., 2010). The gut, like the blood-brain barrier, 
has tight junctions, which when disrupted could allow for absorption of substances that 
could adversely affect brain function (Theoharides & Doyle, 2008). A subset of 
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individuals with autism (36.7%) and their first degree relatives (21.2%) show increased 
intestinal permeability (De Magistris et al., 2010). In addition, individuals with autism 
that have gastrointestinal problems exhibit elevated levels of autoantibodies that bind to 
the intestinal mucosa on the basement membranes of epithelial cells (Torrente et al., 
2004). Autoantibodies may indicate an inflammatory state of the intestines and could in 
turn alter the mucosal barrier and integrity leading to gastrointestinal problems in 
individuals with autism (Coury et al., 2012). This could be another line of evidence for 
systemic infection and chronic inflammation in individuals with autism, where the gut 
and brain together are susceptible to systemic inflammation. Specifically, Buie and 
colleagues (2010) describe a set of beneficial diagnostics for individuals with autism 
spectrum disorders, including guidelines for routine pediatric testing of abdominal pain, 
chronic constipation, and gastroesophageal reflux disease. Coury and colleagues (2012) 
describe the importance of ascertaining whether individuals with autism differ from 
controls in several gastrointestinal features such as the microbiome, metabolites, 
inflammation, neurotransmitters, immune response and mucosal integrity, which may 
lead to possible biomarkers for individuals that may be a risk for developing autism.  
 
Rett Syndrome, Angelman Syndrome and Fragile X Syndrome 
Syndromic autism is described as a single gene disorder that presents autism-like 
features.  Ubiquitin-protein ligase E3A (UBE3A), methyl CpG binding protein 2 
(MECP2), and fragile X (FMR1) are genes associated with syndromes in which 
individuals present the core behaviors of autism (Jellinger et al., 1988; Bonati et al., 
2007; Farzin et al., 2006).  
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Rett syndrome is caused by a mutation of the methyl CpG binding protein 2 
(MECP2) and is almost exclusively found in females. Since MECP2 is found on the X 
chromosome, females have a normal copy of the gene; by contrast, the condition in males 
is generally fatal early in life. It accounts for 1% of children diagnosed with autism 
(Lintas & Persico, 2009). Individuals with Rett syndrome present a lack of 
communication, increased stereotyped behaviors, severe mental retardation, and 
gastrointestinal disorders. It has been reported that individuals with Rett syndrome have 
neuropathology involving increased numbers of astrocytes in the cortex, a decrease in 
dendritic spine density in the cerebral cortex, and a decrease in the number of cerebellar 
Purkinje cells (Armstrong et al., 2005). MECP2 knockout mice exhibit features of Rett 
syndrome, including a decreased life span, reduced body weight, reduced brain weight, 
and behaviors of Rett syndrome which can be assayed in mice using behavioral tests to 
exhibit the extent of the disease (Chen et al., 2011; Guy et al., 2001).  
Angelman syndrome is caused by a deletion on chromosome 15 Q, 2Q 13, which 
most often is the ubiquitin E3 ligase (UBE3A) gene (Wang et al., 2013). UBE3A is an 
imprinted gene in which only the maternal copy is expressed in the brain (Smith et al, 
2011). Angelman syndrome is a neurodevelopmental disorder characterized by ataxia, 
severe learning impairments, and epilepsy. Individuals with Angelman syndrome 
commonly meet the diagnositic criteria for autism based on the autism diagnostic 
observation scale (ADOS) (Bonati et al., 2007). The UBE3A maternal knockout mouse 
model involves deficits in reversal learning, impairments in motor function, hypoactivity, 
and reduced rearing and marble burying (Huang et al., 2013).  By increasing the UBE3A 
gene in the mouse threefold, Smith and colleagues have developed a mouse model that 
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exhibits core autism behaviors including defective social interaction, impaired 
communication and increased stereotypic behaviors as well as altered gluatamatergic 
synaptic transmission, resulting in reduced excitatory transmission (Smith et al., 2011).  
Thus, increasing or decreasing the expression of UBE3A has important behavioral 
consequences relevant to autism (McNamara & Isles, 2013).  These mouse models have 
promise for studying the behavioral features in autism, allowing histological comparative 
analysis, and genetic manipulations, thus providing insights for the genetic and 
environmental factors contributing to autism. 
Fragile X syndrome is caused by mutations in the FMR1 gene and accounts for 1-
3% of the cases of autism. The mutation is an expansion in of the CGG trinucleotide on 
the FMR1gene to a full mutation size of 200 or more repeats, children with autism have 
been reported to have 55-200 CGG repeats (Reddy et al., 2005). Fragile X- associated 
tremor/ataxia syndrome (FXTAS) is progressive degenerative movement disorder with 
the features of tremors, cerebellar gait ataxia, parkinsonism and cognitive decline with an 
onset at age 50 (Hall & O’Keefe, 2012). Often, these individuals have family members 
with fragile X and it occurs in both males and females and often the female carriers have 
45-54 CGG (Hall & O’Keefe, 2012). Individuals with fragile X syndrome exhibit a 
marked Purkinje cell loss, axonal swelling and glial cell loss in the cerebellum (Tassone 
et al., 2004). The female CGG knock-in mice, which are fragile X carriers exhibit deficits 
for learning a skilled forelimb reaching task compared to wild-type littermates, and that 
these deficits worsen with increasing CGG repeat lengths (Diep et al., 2012). The FMR1 
knockout mice exhibit features similar to fragile X and specifically represent behaviors of 
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autism such as impaired social interaction and repetitive behavior (Bernardet et al., 
2006).  
 
Genetics and Inflammation in Mental Illness: Schizophrenia, Sickness Behavior, and 
Depression 
A recent study of genome-wide single-nucleotide polymorphism (SNP) found 
shared SNPs for five major neuropsychiatric disorders including schizophrenia, bipolar 
disorder, autism, major depression and attention deficit hyperactivity disorder, based on 
genetic data from 60,000 subjects worldwide (Cross-Disorder Group of the Psychiatric 
Genomics Consortium et al., 2013). The authors report that SNPs within two L-type 
voltage-gated calcium channel subunits, CACNA1C and CACNB2, had genome-wide 
significance, a model selected analysis supported these loci in several disorders, and 
pathway analysis supported a role for calcium channel signaling genes for all five 
disorders (Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013). 
This finding provides promise for a greater understanding of the disease process in 
mental illness and particularly for investigation for therapeutics in the diseases. It 
provides a common genetic link across the disorders, highlighting the complexity of 
differentiating the pathologies across the different mental illnesses. Moreover, each of 
these diseases has a neuroinflammatory component similar to autism, so understanding 
the genetics and neuroinflammation in these neurodevelopmental and psychiatric 
disorders is essential for developing treatments.  
A genome-wide microarray study of left superior temporal cortex in 
schizophrenic individuals shows a downregulation of immune genes, suggesting that the 
 
17
	  
altered genes related to the immune system may compromise synaptic functioning in the 
region (Schmitt et al., 2011). Moreover, individuals with schizophrenia exhibit executive 
dysfunction, and it is proposed that schizophrenia has a strong neurodevelopmental 
component (Brown et al., 2007). An epidemiological study of maternal infection in 
schizophrenia revealed that mid-gestational influenza is associated with schizophrenia 
(Brown et al., 2000; Brown et al., 2004). A study of autopsy tissue found increased 
activation of microglia labeled by HLA-DR in a subset of cases with schizophrenia 
(Bayer et al., 1999). Microglia analysis in postmortem tissue in the frontal and temporal 
lobes of individuals with schizophrenia shows evidence for both microglial activation and 
degeneration (Wierzba-Bobrowicz et al., 2004). In addition, Wierzba-Bobrowicz and 
colleagues (2005) found evidence of degeneration in microglia cells from schizophrenic 
individuals, including reduction of the cytoplasm, mitochondrial damage, fragmenting, 
and thinner and shortened microglial processes (Wierzba-Bobrowicz et al., 2005). A 
number of postmortem studies show greater evidence of microglia activation and 
infiltration by other immune cells in the brain in individuals with schizophrenia 
(Radewicz et al., 2000; Steiner et al., 2006; Drexhage et al., 2011). In schizophrenia, 
inflammation and possible maternal immune activation plays a key role in the 
neuroinflammation in the brain. 
Another result of a systemic infection is “sickness behavior” which drives an 
increase in signals to the brain causing changes in metabolism, social withdrawal, 
appetite suppression and a general ill feeling. The main pro-inflammatory cytokines 
involved are interleukin-1 beta (IL1B) and tumor necrosis factor alpha (TNF-alpha) 
(Exton et al., 1997; Hart et al., 1998; Perry et. al., 2010). Sickness behavior is another 
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example of how systemic infection and inflammation can alter both the inflammatory 
response and the brain and behavior. There are a number of parallels between sickness 
behavior and major depression, such as the somatic features of fatigue, loss of appetite, 
sleep disturbances, and depressed mood (Dantzer et al., 2009). Elderly individuals with 
depression exhibit elevated levels of inflammatory cytokines, including IL-6, in the blood 
(Trzonkowski et al., 2004). In a postmortem study of microglia in depression there is 
evidence for microglial activation in patients with depression who completed suicide, 
compared to patients who died via other methods and healthy controls (Steiner et al., 
2008). 
It is important to note that each of these mental illnesses is associated with 
neuroinflammation and immune dysregulation, which is a common pathology in autism 
spectrum disorder. Understanding the connection of the neuroinflammation in mental 
illness could advance the therapies for these diseases. 
 
Conclusion 
In this thesis, we explore the density of the microglia in the cerebral  and 
cerebellar cortices of individuals with autism to investigate the hypothesis that 
neuroinflammation is involved in autism. We chose fronto-insular cortex (FI) because 
multiple lines of evidence have previously implicated FI in autism (Allman et al., 2005, 
Di Martino et al., 2009, Santos et al., 2011). Vargas et al. (2005) reported that 
inflammation was widespread throughout the brains of individuals with autism and found 
an increase in inflammatory cytokines in the cerebellum and cerebral cortex in cases with 
autism (Vargas et al., 2005). 
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In our cerebellar study we included additional neurodevelopmental disorders that 
exhibit similar behaviors to autism spectrum disorder and have known cerebellar 
pathology. We found increased microglial density in two disparate cortical regions, 
frontal insular cortex and visual cortex, in individuals with autism (Tetreault et al., 2012). 
Our results imply that there is a global increase in the microglial density and 
neuroinflammation in the cerebral cortex of individuals with autism. We subsequently 
found a more than threefold increase in the microglial density specific to the molecular 
layer of the cerebellum, which is the region of the Purkinje and parallel fiber synapses, in 
individuals with autism and Rett syndrome. Moreover, we report that not only is there an 
increase in the microglia density in the molecular layer, but also, the microglial cell 
bodies are significantly larger in perimeter and area in individuals with autism spectrum 
disorder and Rett syndrome compared to controls, which implies that the microglia are in 
the activated state. 
In addition, we report that an individual with Angelman syndrome and the sibling 
of an individual with autism have microglial densities similar to the individuals with 
autism and Rett syndrome. By contrast, an individual with Joubert syndrome, which is a 
developmental hypoplasia of the cerebellar vermis, had a normal density of microglia, 
indicating the specific pathology in the cerebellum does not necessarily result in 
increased microglial densities. Finally, we found a significant decrease in Purkinje cells 
specific to the cerebellar vermis in individuals with autism thus providing direct 
quantitative evidence for abnormal cerebellar circuitry in this conditions. 
These findings indicate the importance of investigation of the Purkinje synapses 
in autism and that the relationship between the microglia and the synapses is of great 
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utility in understanding the pathology in autism. Together, these data provide further 
evidence for the neuroinflammation hypothesis in autism and a basis for future 
investigation of neuroinflammation in autism. In particular, investigating the function of 
microglia in modifying synaptic connectivity in the cerebellum may provide key insights 
into developing therapeutics in autism spectrum disorder. 
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Abstract We immunocytochemically identified microg-
lia in fronto-insular (FI) and visual cortex (VC) in autopsy
brains of well-phenotyped subjects with autism and mat-
ched controls, and stereologically quantified the microglial
densities. Densities were determined blind to phenotype
using an optical fractionator probe. In FI, individuals with
autism had significantly more microglia compared to con-
trols (p = 0.02). One such subject had a microglial density
in FI within the control range and was also an outlier
behaviorally with respect to other subjects with autism. In
VC, microglial densities were also significantly greater in
individuals with autism versus controls (p = 0.0002).
Since we observed increased densities of microglia in two
functionally and anatomically disparate cortical areas, we
suggest that these immune cells are probably denser
throughout cerebral cortex in brains of people with autism.
Keywords Microglia ! Autism ! Fronto-insular cortex !
Visual cortex
Introduction
The brain is substantially isolated from the body’s immune
system by the blood–brain barrier, which restricts the
passage of most immune cell types and proteins from
capillaries into brain tissue. The brain has its own immune
system based on microglia, which are derived from the
macrophage lineage and reside throughout the brain, where
they mount defenses against invading microorganisms and
clear damaged tissue and metabolic waste (Graeber and
Streit 1990, 2010). This is achieved through phagocytosis,
in which the microglia ingest these substances.
Nimmerjahn et al. (2005), Davalos et al. (2005) and
Wake et al. (2009) directly observed the activity of
microglia in intact living mouse brains using two-photon
microscopy in animals that express green fluorescent pro-
tein specifically in microglia. Their experiments showed
that microglial cell bodies are relatively stationary, but
their fine processes are in constant motion on a minute-to-
minute basis. They observed that the microglial processes
continually probe the immediate area, so that the popula-
tion conducts a complete surveillance coverage of brain
tissue every few hours. When the microglial processes
encounter damaged tissue, metabolic byproducts such as
oxidized lipoproteins, or invading microorganisms, they
respond by expanding and engulfing these substances and
transporting them back to the microglial cell body where
they are stored for an indeterminate period of time. The
microglia contact other types of glia and neurons as part of
their constant surveillance, but when they encounter other
microglia there is mutual repulsion of their processes,
which may account for their relatively uniform spacing.
There is also evidence that microglial processes can strip
synapses away from their dendrites, suggesting that
microglia may have another role in modifying neuronal
connections in development and plasticity (Blinzinger and
Kreutzberg 1968; Graeber et al. 1993; Kreutzberg 1996;
Paolicelli et al. 2011). Wake et al. (2009) reported through
in vivo imaging that microglia make transient direct con-
tact with synapses, and that the frequency of this contact is
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dependent on neural activity. In experiments in visual
cortex, microglia contact frequency was decreased by
silencing the visual input by injecting tetrodotoxin into the
eyes (Wake et al. 2009). Inducing neural degeneration by
transient ischemia increased the duration of microglial
contact with synapses which was followed by synapse
elimination (Wake et al. 2009).
Microglia are closely related developmentally and
functionally to macrophages. Both originate from the
monocyte lineage in the bone marrow. Microglia first
appear in small numbers in the brain during embryogene-
sis, but they emerge prominently during the early postnatal
period when they enter the brain from the bloodstream to
form what has been called the fountain of microglia, in
which they migrate along the course of the fibers of the
corpus callosum to all parts of the brain (Imamoto and
Leblond 1978). The initial population of microglia can be
augmented by subsequent invasion into the brain of cir-
culating macrophages, which apparently assume the mi-
croglial phenotype after entering neural tissue (Schmid
et al. 2009). In a preliminary study of gene expression, we
observed in some of our autistic cases increased expression
of a network of genes centered on interleukin-6 (Tetreault
et al. 2009). Interleukin-6, together with several other
genes in the network, is characteristic of activated versus
quiescent microglia (Thomas et al. 2006). People with
autism have significantly increased cytokines in frontal
cortex and elevated levels of cytokines in the cerebro-
spinal fluid compared to control subjects (Li et al. 2009;
Zimmerman et al. 2005) and there is evidence for immune
system dysfunction in the development of autistic children
(Ashwood et al. 2006; Chez and Guido-Estrada 2010).
These observations motivated us to conduct a quantitative
study of the density of microglia in brains of individuals
with autism compared to controls. Our goal in this work is
to quantify microglial differences between subjects with
autism and age-matched controls in two cortical areas,
fronto-insular cortex (FI) and primary visual cortex (VC).
Multiple lines of evidence have previously implicated FI in
autism (Allman et al. 2005; Di Martino et al. 2009; Santos
et al. 2011); VC was selected because of its functional
difference and anatomical distance from FI, in an effort to
span the diversity within neocortex.
Methods
Tissue Samples
Formaldehyde-fixed (8 % solution) human right FI and
right VC tissue from subjects with autism and controls was
obtained from the NICHD Brain and Tissue Bank for
Developmental Disorders at the University of Maryland-
Baltimore, as shown in Table 1. FI was identified based on
criteria such as the presence of the Von Economo neurons
and sulcal location (Allman et al. 2010) and corresponds to
the posterior part of Brodmann’s area 47. VC was identi-
fied by using the calcarine sulcus as a landmark; the
dissections involved the sulcal lip corresponding to Brod-
mann’s areas 17 and 18. The NICHD Brain and Tissue
Bank for Developmental Disorders provided detailed
clinical records, with personal identification removed, for
each individual with autism whose brain we studied, as
summarized in the phenotypic descriptions in Table 2. To
confirm the diagnosis of autism, the medical records of
each person with autism were reviewed in depth by a
clinical psychologist (EA) who specializes in autism. In
each case we have at least one thorough clinical description
of the subject by either a psychologist or psychiatrist. Ten
of our eleven subjects with autism had the autistic diag-
nostic interview-revised (ADI-R), which is the result of a
structured interview with a parent of the individual with
autism. Three of the individuals with autism had ADIR
records, but the actual scores were not in the file. One
individual with autism had a childhood autism rating scale
and met the criteria for an autism diagnosis. The records
additionally include measures of behavioral development
such as the Bayley tests, as well as a history of medications
and other health issues reported by physicians and clinical
psychologists, described in Table 2.
Sectioning and Immunocytochemistry
Samples were sectioned in the coronal plane at 50 lm on a
microtome with a vibrating blade (Microm HM 650 V) in
0.1 M phosphate buffer solution (PBS) and stored in well
dishes with PBS and sodium azide. The microglia were
immunocytochemically stained with an antibody to IBA1
(ionizing calcium adaptor molecule-1), the gene product of
the Aif1 gene (allograft inflammatory factor 1), raised
against the C-terminus of IBA1, which labels microglia and
monocytes. We used the IBA1 antibody because it yields
excellent and selective staining of microglia in formalde-
hyde-fixed human archival brain tissue (Streit et al. 2009).
The utility of IBA1 for the study of microglia has also been
shown through expression of the IBA1 gene coupled with
enhanced green fluorescent protein in experiments
employing 2-photon microscopy to image the development
and motility of this class of cells in the brains of living
mice (Hirasawa et al. 2005; Wake et al. 2009). We used a
concentration of 1:1,000 of IBA1 antibody (Wako, Code
No. 019-19741). Four batches of immunostaining were
performed including duplicate sections from both FI and
VC of each of the subjects, and each of the staining pro-
cedures showed consistent and robust immunostaining
across the sections. Free-floating sections were rinsed with
J Autism Dev Disord
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PBS and then incubated with 1 % citrate buffer (Chemicon,
cat # 21545) for 30 min at 37 "C for antigen retrieval.
Sections were rinsed with PBS, treated to remove endog-
enous peroxidase activity with 0.75 % hydrogen peroxide
and methanol for 20 min, and then rinsed with PBS. The
blocking step, to eliminate random antibody binding, used
0.1 % Triton X-100, 4 % normal goat serum (NGS), 1 %
BSA, and 3 % dry milk in PBS for 3 h. Primary antibody
was incubated for 38 h at 4 "C in a PBS solution that
included 0.1 % Triton X-100, 2 % NGS and 1:1000 anti-
IBA1. Sections were then rinsed with PBS, incubated with
biotinylated anti-rabbit (BA-1000,Vector Laboratories) at
1:200 for 2 h, and then rinsed again with PBS. A Vecta-
stain Elite ABC kit (pk-6100, Vector Laboratories) was
used for the avidin–biotin-peroxidase method, then sec-
tions were incubated for 30 min. After sections were once
again rinsed with PBS, immunoreactivity was visualized by
using a chromagen, 30-diaminobenzidine and nickel (SK-
4100, Vector Kit). Null control sections were incubated
without primary antibody and incubated with goat IgG at
the same concentration as the primary antibody. No
immunostaining was observed in these control sections.
Quantification of Microglial Densities
Microglial density in FI and VC was measured blind to
phenotype and quantified using the program Stereo Inves-
tigator (MBF Bioscience, Williston, VT) with a Reichert
Polyvar microscope equipped with a motorized stage and a
camera for visualization. All sections were quantified in at
least two separate replications with different regions of
interest, and some sections were quantified up to four times
with both different and identical regions of interest. For all
of the samples, duplicate sections of FI and VC were
classified and quantified for reproducibility. Independent
raters quantified and classified blind random sections to
replicate the method. The represented density measure is
an average of the blind replicated runs. Quantification was
Table 1 Autistic and neurotypical control subjects used for microglial density measurements
ID GUID Age Sex Cause of death Brain weight (g) PMI (h) FI VC
Autistic
M4021 NDAR_INVUX206VRV 3a M Drowning 1,330 15 X X
M4029 NDAR_INVRX268EH4 3b M Drowning 1,130 13 X X
UMB4671 Not provided 4 F Fall from 9th story 1,320 13 X X
UMB797 NDARYX624FEY 9 M Drowning 1,175 12 X
M2004 NDAR_INVAK979XTP 10 M Drowning 1,400 25 X X
UMB4305 NDARWL137ER1 12 M Serotonin syndrome 1,360 13 X
UMB4315 NDAR_INVHD069UM7 14a M Natural 1,590 22 X X
UMB4899 NDAR_INVGW538MM3 14b M Drowning 1,450 9 X X
UMB5278 NDARYH540PL4 15 F Drowning with seizure 1,417 13 X X
UMB4999 Not provided 20 M Cardiac arrhythmia 1,427 14 X
UMB51761 NDARHU383HFF 22 M Subdural hemorrhage 1,525 18 X X
Control
UMB5282 Not provided 2 M Asphyxia 1,345 16 X X
UMB1185 Not provided 4a M Drowning 1,450 17 X X
UMB4670 Not provided 4b M Commoti cordis 1,470 17 X X
UMB5387 Not provided 12 M Drowning 1,750 13 X X
UMB4925 Not provided 13a M Natural 1,650 16 X
UMB917 Not provided 13b M Accident, multiple injuries 1,450 10 X X
UMB4591 Not provided 16 F Multiple injuries 1,330 14 X X
UMB1712 Not provided 20a M Gunshot to chest 1,500 8 X X
UMB4727 Not provided 20b M Multiple injuries Not available 5 X X
UMB1542 Not provided 22a M Multiple injuries 1,510 4 X X
UMB4542 Not provided 22b M Multiple injuries 1,460 8 X X
UMB1713 Not provided 23 M Head and neck injuries 1,600 8 X X
The tissue source is NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD. The letters in
the age column are for the purpose of differentiating subjects of the same age in the graphs in Figs. 2 and 3 PMI post-mortem interval,
X microglia density measurements were made for this structure
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performed within a region of interest that spanned layers
two to six; microglial distribution appeared relatively
homogenous throughout the layers in our samples. Esti-
mated cell counts were performed using the optical dis-
sector probe at 409 magnification (oil immersion
NA = 1.0) with a dissector height of 16 lm (flanked by
2.0 lm guard zones), a counting frame of 260 lm 9
160 lm and a grid size of 425 lm 9 425 lm. To avoid
oversampling, we used the Gunderson counting rule such
that cells intersecting only 3 of the 6 surfaces of the dis-
sector cube were counted. Microglial density per mm3 was
calculated by dividing the optical fractionator estimate of
the number of cells present in the full thickness of the
section within the region of interest by the area of the
region of interest and the thickness at which the section
was cut to account for any tissue shrinkage.
Statistical Analysis
Densities for the subjects with autism and control popula-
tions were compared using the Mann–Whitney test with
two-tailed p value. Correlation levels between replications
were measured using Pearson’s r-squared. Possible con-
founds in the subjects with autism that could alter mi-
croglial densities were examined. Binary confounds,
including whether death was by drowning and whether
seizures were present, were tested using the Mann–
Whitney test; a possible confounding correlation with post-
mortem interval was tested using Pearson’s r-squared.
Results
Figure 1 depicts the stereological method and photomi-
crograph of the microglial quantification method in a brain
of an individual with autism. We found significantly higher
density in the individuals with autism than in the controls
in both FI (p = 0.0206, see Fig. 2) and VC (p = 0.0002,
see Fig. 3). The numbers are represented as the average of
the microglial densities for the multiple replications per-
formed in each individual. Comparisons were made using
Mann–Whitney tests with two-tailed p values. The repeated
quantifications in the same structure are highly signifi-
cantly correlated: for FI, and VC, r2 = 0.6480, p\ 0.0001
(Fig. 4) when the blind replications are from the exact ROI
the correlation is r2 = 0. 9780, p\ 0.0001 for the intra-
rater reliability. Notably, the individuals with autism
cluster together in FI and VC, except for a single outlier
subject with autism, while the controls all cluster together
in both FI and VC.
Figure 2 shows the microglial cell densities in FI of
autistic subjects and controls for the combined and aver-
aged data for both microglial quantifications. Individuals
with autism (n = 10) had significantly higher microglial
density (p = 0.02060) than control subjects (n = 12)
(Mann–Whitney test with two-tailed p value).
The 12-year-old male UMB4305 was a unique case in
this group of people with autism because there was no
increase in microglial density compared with controls.
Although the ADI-R scores for this case are in the autistic
range, he was diagnosed as having pervasive develop-
mental disorder not otherwise specified (PDD-NOS), and,
in addition, with psychosis NOS, and ADHD. UMB4305
was the only one among all subjects tested who was treated
for psychosis, including administration of the drugs que-
tiapine, olzapine, and risperdal (Table 2). For these rea-
sons, we think this individual may have suffered from a
condition distinct from the other individuals who had the
autism diagnosis. According to the neuropathology report
for UMB4305, ‘‘there were three small foci of yellow
discoloration noted in the leptomeninges overlying the
right antero-inferior frontal pole, right gyrus rectus and left
gyrus rectus which measured 0.2 9 0.2 9 0.2 cm. Well-
circumscribed regions of shrinkage and slight yellow dis-
coloration were present in the cortical ribbon underlying
the discolored leptomeninges. … There was necrosis
around the small area of the contusions that included the
entire cortical ribbon through layer one. The small frontal
lobe contusions had visible macrophages surrounded by
Fig. 1 Stereological procedure for quantifying and identifying
microglia in control and the brains of individuals with autism; the
red and green frame defines the borders of the region of interest for
counting microglial cells according to the Gundersen et al. (1988)
procedure. A microglial cell was included if it was in the counting
frame or if the soma crossed the green line and was excluded from the
counting when the cell soma crossed the red line to avoid
oversampling. We used an optical dissector height 16 lm (flanked
by 2.0 lm guard zones) and dissector probe at 409 magnification (oil
immersion NA = 1.0). Some of the cells are out of focus in the
photomicrograph, which is caused by the high numerical aperture of
the lens which creates many depth planes through the tissue which is
necessary for quantifying cells in three dimensions. Immunocyto-
chemical labeling with Iba1 (1:1000, Wako), a specific marker for
microglia and macrophages (Sasaki et al. 2001), in FI of the 14 year
old male with autism (UMB4315) (Color figure online)
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reactive astrocytes observable with a hematoylin-eosin
stained sections.’’ The report noted that beyond these local
contusions, the cortical layers were normal and the neurons
in the cerebral cortex of the fronto-parietal lobe, hippo-
campus, basal ganglia, and cerebellum were unremarkable.
Figure 3 presents similar data for primary visual cortex
(VC). Total microglial densities were significantly greater
in VC for the individuals with autism (n = 9) versus the
control (n = 11) subjects (p = 0.0002 Mann–Whitney test
with two-tailed p value). The increase in microglial density
is present throughout almost our entire sample of subjects
with autism, with ages ranging from 3 years of age to 22.
We address the two exceptions to this broad finding, UMB
1185 and UMB 1713, below.
After measuring microglial densities, we consulted Lyck
et al. (2009) in which the number of microglia in the cortex
of three well-documented neurotypical brains was carefully
and comprehensively quantified using a CD45 antibody
with unbiased stereology. They reported an average of 3.48
billion CD45 positive cells in the entire human neocortex.
Using the estimated value for human neocortical grey
volume from Frahm et al. (1982), which is 584,706 mm3,
one can then estimate the density of microglia in the
neurotypical human cortex by dividing by the total number
of microglia, which is approximately 5,951 (CD45 positive
cells) per mm3 in the total human neocortex (Fig. 5a, b).1
This is close to our estimated microglial densities for
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Fig. 2 Microglial densities in FI in subjects with autism and
neurotypical brains are represented as the average for the replicated
runs. Individuals with autism (n = 10) have a significantly greater
density of microglia, the key cellular participants in the inflammatory
response in the brain, compared to controls (n = 12) p = 0.0206
(Mann–Whitney). LS: known to have spent time on life support.
D: cause of death was drowning. BD: brain damage, brain contusion,
hemorhage, or edema. TD: traumatic death (MVA, fall) with possible
head injury, not explicitly mentioned. OD: drug overdose (not
necessarily cause of death). S: seizures (not necessarily cause of
death). Numbers in black are post-mortem interval in hours
1 In Table 5 of Lyck et al. (2009) the column headed ‘‘total
neocortex’’ refers to the neocortical gray matter only. In their methods
Section 2.2.7, ‘‘Estimation of Cell Numbers,’’ they describe their
selection of the region of interest, saying, ‘‘… followed by delineation
the border between white matter and neocortex at 2109 magnification
(10 9 lens) marking the white matter as ‘exclusive region’,’’
indicating that their cell number estimates were made from a region
that excluded white matter. Further, Fig. 2b from this paper indicates
that the brain slices were segmented into ‘‘frontal neocortex,’’
‘‘temporal neocortex,’’ ‘‘parietal neocortex,’’ ‘‘occipital neocortex,’’
and ‘‘white matter,’’ implying that the various neocortex segments do
not include white matter. Thus, in Table 5 the column heads ‘‘frontal
cortex,’’ ‘‘temporal cortex,’’ etc. presumably refer specifically to the
gray matter portions of those regions, and ‘‘total neocortex’’ (which is
a sum of the other four columns) also includes only gray matter.
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control FI (6,479 microglia per mm3) and control VC
(6,048 microglial cells per mm3). In FI, individuals with
autism had an 18 % higher microglial density compared to
our neurotypical cases, and in VC 21 % higher microglial
density compared to our neurotypical cases.
These findings demonstrate that, at the time of death,
there were significantly higher microglial densities in the
subjects with autism compared to the control subjects, and
that this change in microglial density is widespread
throughout the cerebral cortex in autism. The microglial
densities in FI and VC in the same subject were signifi-
cantly correlated (both measures were available in 10
controls and 8 autistic subjects for a total of 18 subjects)
with Pearson’s r2 = 0.4285, p = 0.0024 (Fig. 6). This
indicates that the elevation in density is consistent between
these areas, and probably throughout the cortex, in both
subjects with autism and controls.
We tested several confounding variables that could alter
microglial densities in FI and VC of the subjects with
autism and found no statistically significant relationship
between microglial density and drowning versus other
causes of death; traumatic versus other causes of death;
having been on life support or not; having a recorded drug
overdose or not; or having had seizures or not (Table 3).
There was no significant difference between the subjects
with autism and controls with respect to age of the subjects
or post-mortem interval (PMI). However, the controls had
significantly greater (p = 0.0328) brain weight (1,501 g)
versus the subjects with autism (1,374 g) (Mann–Whitney
test). This difference was driven mainly by one control
subject (M5387) with very high brain weight (1,750 g).
This is 310 g greater than the average brain weight
(1,440 g) for a 12 year old male (Dekaban 1978), and when
the outlier is removed there is no significant difference in
brain weight between the subjects with autism and the
control subjects. The differences in microglial density
between individuals with autism and controls remain sig-
nificant when the one outlier was removed for density
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measurements (FI, p = 0.0257 and VC, p = 0.0001,
Mann–Whitney tests). In addition, brain weight and mi-
croglial density were not significantly correlated in indi-
viduals with autism compared to control cases for FI and
VC (Table 3). Morgan et al. (2010) found brain weight was
negatively correlated with microglial density in the grey
matter, but that the microglial differences between subjects
with autism and control subjects persisted when they sta-
tistically controlled for brain weight.
Microglial densities were negatively correlated with age
in VC in our controls (Pearson’s r2 = 0.6833, p = 0.0017)
and barely missed statistical significance in FI (Table 3).
Microglial densities thus tend to decrease with age in
controls, while in people with autism the microglial den-
sities remain relatively high and constant with age in both
FI and in VC. Finally, microglial densities in VC in con-
trols were negatively correlated with PMI (Pearson’s
r2 = 0.3952, p = 0.0383) but there was no significant
correlation in VC for individuals with autism, or in FI for
either group (Table 3). Morgan et al. (2010) found that
microglial densities were negatively correlated with PMI
across their subjects as a whole population but not for
controls or people with autism as subgroups.
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We found that FI of two control subjects had unusually
high microglial densities compared to the other controls.
They were UMB1185, the 4-year-old control case, and the
23-year-old control UMB1713, who had suffered from
head and neck injuries. The injuries sustained by
UMB1713 are such that could cause an increase in mi-
croglial density if death was not immediate (Engel et al.
2000, Loane and Byrnes 2010). Both of these individuals
showed increases in microglial densities in FI, but not in
VC. By contrast, our subjects with autism had global
increases in microglial densities, shown both in FI and in
VC. This regional difference suggests the possibility of
injury-related pathology in these two controls.
Discussion
We observed increased densities of microglia in two dis-
parate cortical areas. One possibility is that these increased
densities reflect abnormalities specific to these particular
cortical areas, since there is evidence that each is involved
in autism, or alternatively these results may reflect a
widespread difference that occurs throughout the cortex or
even much of the brain. Consistent with the possibility that
the effect is pan-cortical, Morgan et al. (2010) reported an
increase in microglia in subjects with autism in dorsal
lateral prefrontal cortex (dlPFC) compared to controls, and
found an increase in somal size in microglia in subjects
with autism in grey and white matter. Five of Morgan
et al.’s cases with autism overlap with those used in our
study (Table 4). We found that the subjects with autism we
had in common with Morgan et al. showed an increase in
microglial density in both FI (five subjects in common) and
VC (four subjects in common), which is consistent with
Morgan et al.’s findings in dlPFC. In addition, Morgan
found five of the thirteen individuals with autism had an
increase in microglial activation (Morgan et al. 2010).
Precedent for Morgan’s and our microglial observations
comes from Vargas et al. (2005) who found significantly
more microglial activation in the cerebellum of autistic
brains versus controls and a trend toward more microglial
activation in the middle frontal and anterior cingulate
cortices, although the cortical results were not statistically
significant. One of our individuals with autism was used in
the Vargas study (Table 4) (Vargas et al. 2005).
Our methodologies differed, however, in several
respects from those of Morgan et al. (2010). We quantified
microglia in two cortical regions, FI and VC, consistently
in the right hemisphere, whereas Morgan quantified a sin-
gle region, dlPFC, using either the right or left hemisphere.
The reports of increased microglial densities are consistent,
but there are differences in density measurements in
Morgan’s and our studies. The differences in density
measurements for the individuals with autism and controls
can be attributed to our differing calculations and consid-
eration of the shrinkage factor within the tissue. To account
Table 3 Confound statistics for the autistic cases
Confound FI VC
Drowning FI autistics (6 drowning, 5 non-drowning): total density
drowning versus other COD, p = 0.7619 (ns)
VC autistics (5 drowning, 4 non-drowning): total density
drowning versus other COD, p = 0.2857 (ns)
Seizures FI autistics (4 seizures, 6 no seizures): total density seizures
versus no seizures, p = 0.2571 (ns)
VC autistics (3 seizures, 6 no seizures): total density seizures
versus no seizures, p = 0.7143 (ns)
PMI FI autistics, total density versus PMI, N = 10, Pearson’s
r2 = 0.0658, p = 0.4743 (ns)
FI controls, total density versus PMI, N = 12, Pearson’s
r2 = 0.2628, p = 0.0883 (ns)
VC autistics, total density versus PMI, N = 9, Pearson’s
r2 = 0.00159, p = 0.9189 (ns)
VC controls, total density versus PMI, N = 11, Pearson’s
r2 = 0.3952, p = 0.0383 (significant)
Brian
weight
FI autistics, total density versus brain weight, N = 10, Pearson’s
r2 = 0.0077, p = 0.8095 (ns)
FI controls, total density versus brain weight, N = 11, Pearson’s
r2 = 0.00296, p = 0.6126 (ns)
VC autistics, total density versus brain weight, N = 9, Pearson’s
r2 = 0.1311, p = 0.3384 (ns)
VC controls, total density versus brain weight, N = 10,
Pearson’s r2 = 0.0295, p = 0.6348 (ns)
Age FI autistics, total density versus age, N = 10, Pearson’s
r2 = 0.0080, p = 0.8054 (ns)
FI controls, total density versus age, N = 12, Pearson’s
r2 = 0.3159, p = 0.0572 (ns)
VC autistics, total density versus age, N = 9, Pearson’s
r2 = 0.3477, p = 0.0947 (ns)
VC controls, total density versus age, N = 11, Pearson’s
r2 = 0.6833, p = 0.0017 (significant)
Drowning, seizures, PMI age and brain weight do not account for the increase in microglial density for autistics compared to the controls. The
controls had significantly greater (p = 0.0302) brain weight (1,501.4 g) verses the autistics (1,356.7 g). This difference was driven mainly by
one control subject (M5387) with very high brain weight (1,750 g) which is 310 g greater than the average brain weight (1,440 g) for a 12 year
old male (Dekaban 1978) and when the outlier is removed there is no significant difference (ns) for brain weight comparing the autistic and
control cases. The controls have a significant correlation for microglial density with age in VC (r2 = 0.6833 and p = 0.0017), where over time
the microglia decrease with age and a similar trend occurs in FI but does not reach statistical significance
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for shrinkage, we calculated the microglial density per
mm3 by dividing the optical fractionator estimate of the
number of cells present in the full thickness of the section
within the region of interest by the area of the region of
interest and the thickness at which the section was cut. Our
results for control samples are very close to values calcu-
lated for microglia based on the total number of microglia
in the entire neurotypical cortex determined through ster-
eology (Lyck et al. 2009) and cortical volumes (Frahm
et al. 1982) (see Fig. 5a, b).
The differences between our study and Vargas et al.
(2005) are that they stained microglia with an antibody to
HLA-DR and used an area fraction quantification method
based on the Delesse sampling procedure (Gundersen et al.
1988). That method gives an estimate of the fractional area
of the region of interest covered by the cell type being
measured. The Delesse method does not, however, produce
cell numbers or three-dimensional densities. By contrast,
we stained with an antibody to IBA1 and measured
microglial density in our tissue. Though the specifics of
antibody and methods differed, our data taken together
with Vargas et al. (2005) and Morgan et al. (2010) point to
elevated microglial density in autism, possibly involving
the entire cerebral and cerebellar cortices. This argues that
further investigation of microglial abnormalities and the
microglial pathways in people with autism may be
important for understanding the cellular basis of the autism
phenotype.
There are also some caveats. We cannot be sure that
IBA1 stains all microglia, and there is evidence for
microglial heterogeneity (Carson et al. 2007; Mittelbronn
et al. 2001; Schmid et al. 2009). However, the spacing of
the stained microglia we have observed is consistent with
complete coverage of a relatively regular array of microglia
in the cortex. In addition, we found microglial densities in
control FI and VC that are near the expected densities
calculated from Lyck et al. (2009) and Frahm et al. (1982).
On average the individuals with autism had 18–21 %
higher microglial density in FI and VC compared to neu-
rotypical subjects. How and when does the increased
density of autistic microglial arrays arise, and how is it
maintained? Of course we have no data prior to the time of
death, but the consistency of results among 10 subjects
with autism of differing ages argues that people with aut-
ism have developed a remarkably stable steady-state
microglial density. Given the age range, this is probably
established before age three. It is not clear how long the
increase in microglia persisted in each of the subjects with
autism, but our results show that control subjects have a
significant negative correlation between microglial density
in VC and age, indicating that microglial densities nor-
mally decrease throughout childhood and early adulthood
in neurotypical subjects. However, in people with autism,
there is a relatively steady condition of increased microg-
lial density from childhood into adulthood. It seems pos-
sible that some persistent stimulus is the cause of this
sustained higher level of microglial density in the subjects
with autism. Imaging experiments of quiescent microglia in
intact living cortex suggest that they conduct a complete
surveillance of the cortex every few hours (Davalos et al.
2005; Nimmerjahn et al. 2005). The greater density, and
thus closer spacing of the microglia, in brains of individ-
uals with autism compared with control brains, suggests
that this surveillance is more intense in autism.
Sickness behavior results from systemic infection and/or
inflammation, driving an increase in signals to the brain
that cause changes in metabolism, social withdrawal,
appetite suppression and a general ill feeling (Exton 1997;
Hart 1998; Perry 2010). Sickness behavior is another
example of how a systemic infection or its related
Table 4 Autistic cases used in the Vargas, Morgan and our study for microglial densities
ID GUID Vargas et al. (2005) Morgan et al. (2010) Tetreault et al. (this study)
UMB797 NDARYX624FEY X X X
M4021M NDAR_INVUX206VRV X X
M4029M NDAR_INVRX268EH4 X X
M2004M NDAR_INVAK979XTP X X
UMB4899 NDAR_INVGW538MM3 X X
UMB4671 Not provided X
UMB4305 NDARWL137ER1 X
UMB4315 NDAR_INVHD069UM7 X
UMB5278 NDARYH540PL4 X
UMB4999 Not provided X
UMB5176 NDARHU383HFF X
For this study we quantified two regions in cortex, FI and VC which have not previously been quantified and showed that six additional autistic
cases have increased microglial density measures. An X indicates that the subject was evaluated in the study
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inflammation can alter both behavior and the inflammatory
response in the brain. There is evidence that maternal viral
infection in the first trimester and bacterial infection in the
second trimester are correlated with an increase in off-
spring reported to have autism (Atlado´ttir et al. 2010). In a
recent microarray analysis of gene expression in brains of
individuals with autism compared to controls, Voineagu
et al. (2011) found a module of enriched immune and
microglial genes, although these genes have not been found
in genome wide association studies that have sought to
identify genes that predispose to autism. Voineagu et al.
(2011) conclude that the enriched gene expression of
immune and microglial genes observed in their study has a
non-genetic etiology and may reflect internal or external
environmental influences, which suggests the possibility
that the sustained higher levels of microglia density in
people with autism may also be environmentally mediated.
Chez and Guido-Estrada (2010) report that a subset of
people with autism have a consistent pro-inflammatory
condition of the brain and cerebral spinal fluid and pro-
posed that a systemic infection of the mother may lead to
inflammation in the brain and autism. A recent report from
Wei et al. (2011) found an increase of IL6 in cerebellar
cortex in subjects with autism, which could alter cell
migration and disrupt imperative circuits for normal
development (Wei et al. 2011). In a mouse model of
maternal infection for offspring brain development, it has
been reported that offspring from a mother having a single
injection of IL6 during pregnancy alters fetal brain devel-
opment (Smith et al. 2007) which indicates that a maternal
infection can impact brain development and may play a
critical role in autism. Girard et al. (2010), using a lipo-
polysaccharide (LPS) mouse model of maternal inflam-
mation, found that a single treatment of an IL-1 receptor
antagonist, concurrent with the LPS injection, had the
result that the IL-1 receptor antagonist protected against
maternal placental inflammation and the offspring had
normal brain development. Furthermore, it is well docu-
mented that peripheral infection can dysregulate inflam-
mation in the brain and increase monocyte infiltration into
the cerebral cortex (D’Mello et al. 2009); it is also reported
that people with autism have elevated levels of cytokines
(Chez and Guido-Estrada 2010) which may disrupt the
homeostatic balance in the cortex resulting in a greater
density of microglia.
Are Microglia Predators or Protectors?
The increased microglial densities we observed in the
cortices of our subjects with autism appear to be a robust
discriminator between the brains of people with autism
versus neurotypical brains, and these findings raise a major
question. Are markedly increased numbers of microglia
among the originators of the pathologic processes in aut-
ism, or are they a response (perhaps even a protective one)
to some other aspects of this condition? Microglia have
neuroprotective functions including the phagocytosis of
invading microorganisms and metabolic waste. The
increase of microglial densities in individuals with autism
could be a function of neuroprotection in response to
harmful microorganisms.
In contrast, microglia can also phagocytize synapses and
whole neurons, thus disrupting neural circuits. For exam-
ple, when the axons of motor neurons are cut, the microglia
strip them of their synapses (Blinzinger and Kreutzberg
1968; Cullheim and Thams 2007; Graeber et al. 1993).
Another example of the disruption of circuitry arises from
the direct phagocytosis of neurons. Neurons communicate
with microglia by emitting fractalkine, which appears to
inhibit their phagocytosis by microglia. Deleting the gene
for the microglial fractalkine receptor (Cx3cr1) in a mouse
model of Alzheimer’s disease has the effect of preventing
the microglial destruction and phagocytosis of layer 3
neurons that was observed in these mice in vivo with
2-photon microscopy (Furhmann et al. 2010). In particular,
Cx3cr1 knockout mice have greater numbers of dendritic
spines in CA1 neurons, have decreased frequency sEPSCs
and had seizure patterns which indicate that deficient
fractalkine signaling reduces microglia-mediated synaptic
pruning, leading to abnormal brain development, immature
connectivity, and a delay in brain circuitry in the hippo-
campus (Paolicelli et al. 2011). In summary, the increased
density of microglia in people with autism could be pro-
tective against other aspects of this condition, and that a
possible side-effect of this protective response might
involve alterations in neuronal circuitry.
Microglial Defects as Causes of Disease
By contrast, there are diseases that arise from intrinsic
defects in the microglia themselves which can cause ster-
eotypic behavioral dysfunctions. A naturally occurring
genetic defect in human microglia is the cause of a
remarkable neuropsychiatric disease that was first observed
in Japan and Finland, but has subsequently been found
throughout the world. Nasu-Hakola disease is caused by a
defect in the gene TREM2 or DAP12 which together form
a receptor complex which is strongly expressed in
microglia but not in astroglia or oligodendroglia (Paloneva
et al. 2002; Sessa et al. 2004). In the Allen Brain Atlas,
DAP12 is preferentially expressed in olfactory, anterior
cingulate, and insular cortices in the mouse (http://mouse.
brain-map.org/experiment/show/70523695). These defects
in TREM2 or DAP12 impair the capacity of the microglia
to phagocytose damaged tissue and increase the secretion
of inflammatory cytokines in the olfactory, insular and
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cingulate cortices resulting in microglia-mediated dementia
specific to these structures (Bianchin et al. 2004; Neumann
and Takahashi 2007). Bianchin et al. (2004) report that at
around age 35 in affected patients there are: ‘‘[i]ncipient
personality changes that can only be noticed by relatives
and close friends. The behavioral alterations then become
progressively more evident during the next months. The
patients start to present silly and facetious behavior, lack of
insight, social inhibition, and other unrestrained behavior.
Sometimes they seem to have a euphoric attitude and are
easily distractible, seemingly lacking adequate associated
emotional components. As the disease progresses, the
patients evolve to a state of profound dementia.’’ The
remarkable behavioral specificity of the microglial defect
in Nasu-Hakola disease shows that the microglia can
influence social behavior in a highly specific manner.
Another stereotypic behavioral defect arising from
abnormal microglia is obsessive grooming in mice with a
mutation of the gene Hoxb8 (Chen et al. 2010). Hoxb8 is
expressed only in the microglia in the adult mouse brain,
and these cells originate in spinal bone marrow (Chen et al.
2010). When adult mice with the Hoxb8 mutation were
irradiated so as to kill the bone marrow and then received
bone marrow transplants with the intact gene, the mice
recovered from their excessive grooming pathology, their
skin lesions healed, and their fur grew back to normal.
When normal mice were irradiated and received bone
marrow from donors with the mutated Hoxb8 gene, they
developed the excessive grooming pathology. With these
experiments and a variety of other elegantly executed
controls, Chen et al. (2010) demonstrated that the Hoxb8
mutation with expression restricted to the microglia caused
the pathological grooming behavior. This behavior
resembles obsessive–compulsive disorder in humans,
which involves abnormalities in orbito-frontal and anterior
cingulate cortices (Graybiel and Rauch 2000). These
structures are also implicated in autism (Allman et al.
2005; Di Martino et al. 2009; Santos et al. 2011; Simms
et al. 2009). The excessive grooming in the Hoxb8 mice is
also reminiscent of the stereotypical behaviors that are
commonly found in a subset of individuals diagnosed with
autism (Goldman et al. 2009).
Together with the striking changes in social behavior
present in Nasu-Hakola disease, these data suggest that the
circuitry of anterior cingulate and orbito-frontal cortices
may be particularly sensitive to the disruptive effects of
abnormal microglia. A strong association between reduced
activity in the anterior cingulate and anterior insular cor-
tices (adjacent to orbito-frontal cortex) in social tasks in
subjects with autism versus controls was revealed in a
meta-analysis of 24 functional imaging studies (Di Martino
et al. 2009), and the reduced activity in these structures in
autism may also be related to the apparent vulnerability of
these structures to microglial disruption. This vulnerability
might also be related to the preferential expression DAP12
in the anterior cingulate and insular cortices. Area FI
investigated in our study corresponds to the ventral part of
anterior insular cortex. Thus, while changes in microglial
density appear to be widespread in brains of autistic indi-
viduals, some areas may be more vulnerable than others to
its effects.
Visual Abnormalities in Autism
When we began this investigation we anticipated microglial
abnormalities in the frontal cortices because many lines of
evidence suggest that these structures are involved in autism
(Allman et al. 2005; Courchesne and Pierce 2005; Di Mar-
tino et al. 2009). We included visual cortex based first on its
lack of involvement in prominent social and homeostatic
functions and its physical distance from FI. Yet, abnormal-
ities in visual behavior are among the first signs of autism in
infancy. Beginning at the end of the first year, the earliest
signs of autism include atypical eye contact and visual
tracking, and prolonged fixation, a tendency to perseverate
visual attention on an original stimulus when presented with
a competing stimulus (Zwaigenbaum et al. 2005).
The increased microglial densities in visual cortex may
be representative of a pan-cortical microglial phenotype
related to the autistic phenotype associated with perceptual
integration. In Kanner’s original description of autism he
emphasized his patients’ intense fixation on detail and
‘‘inability to experience wholes without full attention to the
constituent parts’’ as a characteristic feature of the disorder
(Kanner 1968). Frith (2004) drew attention to the tendency
for typically developing children and adults to process
information for meaning and gestalt (global) form, often at
the expense of attention to or memory for details and
surface structure. Happe and Frith (2006) proposed that
autistic subjects show ‘‘weak central coherence,’’ a pro-
cessing bias favoring local information, and a relative
failure to extract the gist or ‘‘see the big picture’’ in
everyday life. The tendency of individuals with autism to
focus on detail at the expense of global perceptions has
been experimentally verified in many studies and may
account in part for impairments in the recognition of faces
(Behrmann et al. 2006; Happe and Frith 2006).
This difficulty perceiving the gist or global features of a
stimulus configuration by subjects with autism may be
analogous to the difficulties experienced by subjects with
autism in making rapid intuitive decisions (Allman et al.
2005). A variant of the ‘‘weak coherence’’ theory applied to
frontal lobe function and specifically linked to activated
microglia and their possible role in altering the development
of this structure was proposed by Courchesne and Pierce
(2005). Happe and Frith (2006) propose that ‘‘weak
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coherence’’ in autism is due to reduced connectivity
throughout the brain due to lack of synchronization of neural
activity (Brock et al. 2002) or lack of connecting fibers (Just
et al. 2004) or lack of top-down connections (Frith 2004). A
similar disruption of global connectivity might disrupt the
integrative functions of FI in social behaviors as suggested
by the reduced activity in this area in subjects with autism
versus controls (Allman et al. 2010; Di Martino et al. 2009).
An increased density of microglia throughout the cortex in
people with autism might contribute to these phenomena
through alterations in the neuronal circuitry.
Summary
We found significantly increased microglial densities in
individuals with autism in two widely separated and
functionally different cortical areas, FI and VC. In light of
our findings, as well as increased densities in the cerebel-
lum (Vargas et al., 2005) and dorsal lateral prefrontal
cortex (Morgan et al. 2010), we propose that microglial
densities are elevated throughout the cerebral and cere-
bellar cortices in individuals with autism. Future studies are
needed to explain the mechanisms responsible for the
increased densities and the relationship between this phe-
nomenon and the behavioral manifestations of autism.
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CHAPTER 3: MICROGLIAL AND PURKINJE CELL DENSITIES IN THE 
CEREBELLAR CORTEX IN AUTISM, RETT, ANGELMAN, AND JOUBERT 
SYNDROMES 
 
Abstract  
Numerous studies report alterations in the cerebellum in autism spectrum disorder 
(Palmen et al., 2005; Fatemi et al, 2012). The pioneering study by Vargas et al. (2005) 
revealed evidence for microglial expansion and increased cytokines in the cerebellum of 
subjects with autism, which suggested the presence of neuroinflammation in this 
structure. Microglia, the immune cells in the brain, are the first defense against infection, 
and phagocytize foreign debris. In addition, microglia are essential for normal 
development and synaptic remodeling. We investigated the neuropathology of the lateral 
cerebellum and vermis in individuals with autism, as well as Rett syndrome, Angelman 
syndrome, and Joubert syndrome, since each of these neurodevelopmental disorders have 
similar behavioral phenotypes as autism spectrum disorder. We found a significant 
increase in the microglia density in the molecular layer, the location of Purkinje synapses, 
in individuals with autism and Rett syndrome. In addition, we found a significant 
reduction in the vermal Purkinje cells in individuals with autism. Future studies dedicated 
to the neuroinflammation in autism are essential. In particular, investigating the function 
and modification of microglia on synaptic connectivity in the cerebellum is crucial for 
developing therapeutics in autism spectrum disorder.  
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Introduction  
Neuroinflammation has been widely reported in autism spectrum disorder (Vargas 
et al. 2005, Pardo et al. 2005, Zimmerman et al. 2005, Wei et al. 2011, Morgan et al. 
2011 and Tetreault et al. 2012). Neuroinflammation is classically defined as an activation 
of microglia and astrocytes and the increased production of cytokines such as Interleukin-
6 (IL6), and Tumor Necrosis Factor-alpha (TNF-alpha) (Monnet-Tschudi et al. 2011). 
Thomas and colleagues report that a gene network, including IL6 and several other genes, 
is characteristic of activated versus quiescent microglia (Thomas et al. 2006). Findings 
show that individuals with autism have significantly increased cytokines in frontal cortex 
and elevated levels of cytokines in the CSF compared to control cases (Li et al. 2009; 
Zimmerman et al. 2005). In the development of children with autism there is there is 
evidence for immune system dysfunction (Ashwood et al. 2006; Chez and Guido-Estrada 
2010). The pioneering studies by Vargas et al. (2005) report inflammation is widespread 
throughout the brains of individuals with autism, finding an increase in inflammatory 
cytokines in the cerebellum and cerebral cortex in cases with autism (Vargas et al. 2005). 
In particular, there is evidence that microglia cells are elevated in the cerebellar cortex 
and cerebral cortex of patients with autism (Vargas et al. 2005, Morgan et al. 2011 and 
Tetreault et al. 2012). The classical role of microglia is to provide defense against 
organisms invading the CNS and clear the waste through the process of phagocytosis 
(Garber and Streit 1990, 2010). Microglia are the brain’s immune responders and 
defenders. In a previous study, investigators reported an increase in HLA-DR labeled 
microglia in the gray and white matter of the cerebellar cortex in human postmortem 
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tissue of individuals with autism compared to controls (Vargas et al. 2005). More 
recently, reports of increased microglia in individuals with autism compared to controls 
in the visual cortex and fronto-insular cortex, two disparate areas, suggest a global 
increase in microglia throughout the cerebral cortex (Tetreault et al. 2012). Wei and 
colleagues (2011) described an increase of IL6 in the cerebellum of individuals with 
autism and hypothesize that the elevated IL6 activates microglia for the function of 
synaptic pruning of the Purkinje cells.  
Microglia are known to function not only as inflammatory cells and macrophages 
for the central nervous system but also in synaptic pruning and plasticity (Wake et al. 
2009, Schafer et al. 2012). Studies using two-photon imaging of fluorescently labeled 
microglia in mouse brains show the microglia are actively probing microzones of brain 
tissue and responding to neuronal stimuli by retracting and expanding their processes 
(Nimmerjahn et al. 2005, Davalos et al. 2005 and Wake et al. 2009). Synaptic plasticity, 
the hallmark of neuronal function and network organization, is regulated by the alteration 
in the number of synapses. In development, synaptic pruning occurs at crucial timing for  
proper brain function and development of cortical and cerebellar networks; the pruning of 
synapses is an active process of microglial cells in particular in early stages in 
development and throughout life (Blinzinger and Kreutzberg 1968; Graeber et al. 1993; 
Kreutzberg 1996; Paolicelli et al. 2011; Schafer et al, 2012). Microglia make contact with 
synapses at a frequency dependent on the activity of the neurons (Wake et al. 2009). In a 
model of neuronal degeneration, microglia contact synapses more frequently and actively 
remove synapses of degenerating cells (Wake et al. 2009). It appears that individuals with 
autism have chronic neuroinflammation, which could disrupt the central nervous system 
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connections and alter networks and contribute to synaptic alteration and cell death (Wood 
2003, Streit et al. 2004).  
In addition to the neuroinflammation in the cerebellum reported in individuals 
with autism, there have been several studies that report cerebellar histopathology in 
individuals with autism. In particular, the Purkinje cells, the only output cells from the 
cerebellar cortex, have been reported to show reduced size and number in individuals 
with autism compared to controls (Ritvo et al. 1986, Bauman and Kemper 2005, Bailey et 
al. 1998, Fatemi et al. 2002, Wegiel et al. 2013). The increased neuroinflammation and 
reduced numbers of Purkinje cells in the cerebellum of individuals with autism, 
compared to controls, inspired this study.  
We set out to investigate the role of inflammation in the cerebellum in autism 
spectrum disorder using human postmortem tissue from the lateral cerebellum and the 
vermis obtained from the NICHD Maryland Brain Bank for Developmental Disorders. 
We quantified microglial volume densities, Purkinje cell linear densities and granule cell 
volume densities in the cerebellum of well-phenotyped individuals with autism (n=10) 
and controls (n=11). In addition, we measured the size and shapes of the microglia somas 
and Purkinje cell somas in individuals with autism compared to controls. We also 
investigated several individuals with rare conditions related to autism (Schwichtenberg et 
al. 2013, Jellinger et al. 1988, Bonati et al. 2007, Clayton-Smith and Laan 2003, Holroyd 
et al. 1991). We included an individual who was one member of a triplet set, another 
member of which had autism. This individual had been carefully evaluated for autism but 
was diagnosed with social anxiety disorder. We also studied three individuals with Rett 
syndrome, an individual with Angelman syndrome and an individual with Joubert 
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syndrome. Our goal in this study is to better understand the role of neuropathology of the 
cerebellum in autism spectrum disorder and other related neurodevelopmental disorders.  
 
Methods  
Tissue Samples  
NICHD Brain and Tissue Bank for Developmental Disorders at the University of 
Maryland-Baltimore provided postmortem formaldehyde-fixed (8% solution) human 
lateral cerebellum and vermis, as shown in Table 1. The NICHD Brain and Tissue Bank 
for Developmental Disorders provided detailed clinical records for each individual with 
autism whose brain we studied, as summarized in the phenotypic descriptions in Table 2. 
To confirm the diagnosis of autism the medical records of each individual with autism 
was reviewed by a clinical psychologist (EA) who specializes in autism. For each 
individual with autism we have at least one thorough clinical description of the subject by 
either a psychologist or psychiatrist. Most of our subjects with autism had the Autistic 
Diagnostic Interview-Revised (ADI-R), which is the result of a structured interview with 
a parent of the individual with autism. In addition, the records include measures of 
behavioral development, a history of medications and other health issues reported by 
physicians and clinical psychologists, described in Table 2. For the sibling of an 
individual with autism, and for individuals with Rett, Angelman, and Joubert syndromes, 
the medical records are also described in Table 2. In addition, genetic information was 
provided for two of the individuals with Rett syndrome and the individual with 
Angelman syndrome. Each of these developmental disorders was specifically chosen for 
the behavioral similarities to autism and previous reports of abnormalities in the 
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cerebellum (Schwichtenberg et al. 2013, Jellinger et al. 1988, Bonati et al. 2007, Clayton-
Smith and Laan 2003, Holroyd et al. 1991). In particular, investigating behaviorally 
similar disorders to autism allows for the inquiry of whether there are core features in the 
neuropathology of the cerebellum across the different disorders.  
Sectioning and Staining  
Tissues were sectioned in the parasagittal plane at 50 µm on a microtome with a 
vibrating blade (Microm HM 650V) in 0.1 M phosphate buffer solution (PBS) and stored 
in well dishes with PBS and sodium azide until used for staining. The microglia were 
immunocytochemically stained with an antibody specific to IBA1 (ionizing calcium 
adaptor molecule-1) as previously described in Tetreault et al. (2012). Each case was 
Nissl stained with 1% cresyl violet for visualization of neurons. Nissl stained sections 
were used for the Purkinje cell counts, Purkinje cell shape analysis, and granule cell 
counts.  
Quantification of Microglial Densities  
Microglial density in the cerebellum was measured blind to phenotype and 
quantified using the program Stereo Investigator (MBF Bioscience, Williston, VT) with a  
Reichert Polyvar microscope equipped with a motorized stage and a camera for 
visualization. The molecular cell layer and granule cell layer microglial were quantified 
as two separate regions of interest per sample to compare the microglial densities in the 
different cerebellar layers. A subset of sections was quantified in two separate 
replications with the same regions of interest. Adjacent sections of cerebellum were 
quantified as assays for reproducibility. Independent raters also quantified random 
sections as another assay for reproducibility. The represented density measure is an 
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average of the blind replicated runs for the section. For the microglial quantification, we 
used the same method as the quantification for cortex previously reported by Tetreault et 
al. (2012) to directly compare the microglial density in the cerebellum with the cortex, as 
shown in Figure 1. Estimated cell counts were performed using the optical dissector 
probe with a 40X objective (oil immersion NA=1.0) with a dissector height of 16 µm 
(flanked by 2.0 µm guard zones), a counting frame of 260 µm x 160 µm and a grid size 
of 425 µm x 425 µm. To avoid oversampling, we used the Gunderson counting rule such 
that cells intersecting only three of the six surfaces of the dissector cube were counted. 
Microglial density per mm3 was calculated by dividing the optical fractionator estimate of 
the number of cells present in the full thickness of the section within the region of interest 
by the area of the region of interest and the thickness at which the section was cut to 
account for tissue shrinkage (Tetreault et al. 2012). When the blind replications are from 
the exact ROI for the cerebellar microglial counts the correlation is r=0. 9370, P< 0.0001 
for the intra-rater reliability.  
 
Microglia Shape Analysis  
The investigator, who was blind to case phenotype, outlined the microglial somas 
using Neurolucida software (MBF Bioscience, Williston, VT). For each case, 50 
microglia somas were traced using a 100X objective and analyzed for size and shape for 
the molecular layer and an additional 50 for the granule cell layer. The cells were 
randomly chosen using the stereological probe designed for the microglial counts. The 
measurements for the shape analysis were area, perimeter, Feret maximum, Feret 
minimum, aspect ratio, compactness, roundness, convexity, shape factor, form factor and 
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solidity. The average for the 50 cells was taken for each of the measurements for 
molecular and granule cell layers for each sample. The means for the groups were 
measured and analyzed.  
 
Purkinje Cell Counts  
Linear quantification of the Purkinje cells was measured for each of the cases 
using Neurolucida software (MBF Bioscience, Williston, VT) and the investigators were 
blind to the case phenotype. A subset of sections was quantified in two separate 
replications with same regions of interest. Adjacent sections of cerebellum were 
classified and quantified for reproducibility. Independent raters quantified and classified  
blind random sections to replicate the method. The entire Purkinje cell layer was traced, 
and 100 percent of the cells were counted in the Purkinje cell layer for the section, as 
shown in Figure 3. The number of Purkinje cells is represented per mm and is calculated 
by the total number of cells counted in the Purkinje cell layer divided by the total length 
of the Purkinje cell layer for the section. The reproducibility for the two independent 
raters of the Purkinje cell counts are significantly correlated with coefficient r= 0.9866 
and a p-value < 0.0001 for the intra-rater reliability.  
 
Purkinje Cell Shape Analysis  
For the Purkinje cell shape analysis, the investigator was blind to case phenotype. 
The Purkinje cells were traced and analyzed using Neurolucida software (MBF 
Bioscience, Williston, VT). For each case, 100 Purkinje cells were traced and analyzed 
for size and shape. The measurements included area, perimeter, Feret maximum, Feret 
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minimum, aspect ratio, compactness, roundness, convexity, shape factor, form factor and 
solidity. The average for the 100 cells was taken for each of the measurements for each 
sample. The means for the groups were measured and analyzed.  
 
Granule Cell Counts  
Granule cell density in the cerebellum was measured blind to phenotype and 
quantified using the program Stereo Investigator (MBF Bioscience, Williston, VT) with a 
Nikon Eclipse 80i microscope equipped with a motorized stage and a camera for 
visualization. Samples used for granule cell measurements were the same as for Purkinje 
cell measurements. The granule cell layer was traced at 10X magnification around one 
leaflet of the cerebellum, with boundaries at the Purkinje cell layer and the deep 
cerebellar nuclei. Estimated cell counts were performed using the optical dissector probe 
at 100X magnification (oil immersion NA=1.0) with a dissector height of 6 µm (flanked 
by 1.0 µm guard zones), a counting frame of 20 µm x 20 µm and a grid size of 200 µm x 
200 µm. The top of the section was refocused at each counting site. To avoid 
oversampling, the Gunderson counting rule was applied so that cells intersecting only 
three of the six surfaces of the dissector cube were counted. Granule cell density per mm3 
was calculated by dividing the optical fractionator estimate of the number of cells present 
in the full thickness of the section within the region of interest by the area of the region of 
interest and the thickness at which the tissue was cut to account for tissue shrinkage.  
 
Statistical Analysis  
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All statistical analysis was done using InStat Statistical Software (GraphPad Software, 
Inc., La Jolla, CA). A Mann-Whitney test with a two-tailed P value was used to compare 
the microglial densities, Purkinje cell linear measurements, and granule cell densities 
between the groups, which included individuals with autism and Rett syndrome and the 
control subjects. In addition, the Mann-Whitney test with a two-tailed p value was used to 
compare the differences between groups for the microglia cell shape analysis and 
Purkinje cell shape analysis. Pearson’s correlation was used to measure correlations for 
the microglial cell counts, Purkinje cell counts and the granule cell counts in the 
individuals, correlations for the cell counts and the ADI-R scores, and correlations for 
individuals that had both microglial density measurements in the cortex and microglial 
density measurements in the cerebellum. Possible confounds in the subjects with autism 
that could alter their microglial density, Purkinje cell linear measurements and granule 
cell densities were examined. Binary confounds, including whether death was by 
drowning and whether the subject had seizures, or had taken medication, the subject’s 
brain weight, and the subject’s post-mortem interval were tested using the Mann-Whitney 
test; a possible confounding correlation with post-mortem interval was tested using 
Pearson’s r- squared, as shown in Table 6.  
Results  
Figure 5 depicts the average microglial densities in frontoinsular cortex (A), 
visual cortex (B), the cerebellar granule cell layer (C) and the cerebellar molecular layer 
(D). Previously reported by Tetreault et al. (2012), individuals with autism have 
significantly greater microglial density in the frontoinsular cortex (18%) and visual 
cortex (21%) compared to neurotypical cases. In both vermis and lateral cerebellum, 
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there was no difference in microglial densities in the granule cell layer in individuals with 
autism compared to controls. There were, however, significantly greater (P=0.0009, two 
tailed t- test) microglia densities in the molecular cell layer in both vermis and lateral 
cerebellum in individuals with autism (n=9) compared to controls (n=9). Microglia 
density was 69% greater in the molecular layer in individuals with autism compared to 
controls, a more than threefold increase than in FI and VC in individuals with autism 
compared with controls. Since the NICHD Brain and Tissue Bank for Developmental 
Disorders provided all the tissue for autistic and control cases, we were able to directly 
compare microglial counts in the cortex and cerebellum for a number of cases (autistics 
n=6 and controls n=5) using the same method, as shown in Table 3. The cerebellum for 
both controls and autistics has significantly greater microglia density (P< 0.0000001, two 
tailed t-test) compared to the density of microglia in the cortex. When comparing the 
correlations of microglial densities in the same individuals where both cortical and 
cerebellar microglia measurements were made, no significant correlations were found.  
[Figure 5 Top]  
Figure 6 exhibits the microglial cell densities for the molecular cell layer and the 
granule cell layer where each data point represents the average for an individual. The 
microglial cell densities are an average of the vermis and lateral cerebellum for an 
individual since there were no significant differences in the microglial densities for the 
two regions. The individuals with autism (n=9) have significantly greater microglia 
densities for the cerebellar molecular layer with an average of 24,611 microglial per mm3 
compared to the controls (n=9) with an average of 14,090 microglia per mm3 (p value is 
0.0009, two tailed t-test). The individuals with Rett syndrome (n=3) have a significantly 
 
57
	  
greater microglia density in the molecular layer, with an average of 29,764 microglia per 
mm3, compared to controls (n=9), with an average of 14,090 microglia per mm3 (p < 
0.0001, two tailed t- test). In addition, there was no significant difference in the 
microglial densities when comparing the individuals with autism (n=9) and individuals 
with Rett syndrome (n=3). We considered the possibility that the high density of 
microglia in the individuals with Rett syndrome might be due small brain size in these 
cases. The microglial density in the Rett syndrome cases is 2.1 times that of the controls. 
The average brain size in the Rett syndrome cases is 927 grams compared with 1404 
grams in the controls and thus the Rett syndrome brains are 2/3rds of the weight of the 
controls, which is not sufficient to explain the microglial density differences.  
The individual with Angelman syndrome (n=1), with a microglia density of 
37,263 mm3, and sibling of an individual with autism (n=1), with a 29,764 mm3 
microglia density in the molecular layer of the cerebellum, each had densities similar to 
the individuals with autism and Rett syndrome. The individual with Joubert syndrome 
(n=1) had the lowest microglial densities in the molecular layer (6,168 mm3) of all the 
subjects. Thus, the microglial densities in the molecular layer for the individuals with 
Rett and Angelman syndromes are in the high end of the range for the individuals with 
autism, whereas the densities for the individual with Joubert syndrome are lower than for 
any control case.  
[Figure 6 Top]  
There was a significant increase in the microglia soma perimeter (p=0.037, two 
tailed t-test) and area (p=0.042, two tailed t-test) in the molecular layer in the individuals 
with autism (n=8) compared to controls (n=8), illustrating that individuals with autism 
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have larger microglia somas in the molecular layer than controls. The same is true for the 
individuals with Rett syndrome (n=3) where the microglia soma area (p=0.017, two tailed 
t-test) and perimeter (p=0.004, two tailed t-test) are significantly larger than controls 
(n=8) in the molecular layer. There is no significant difference between the individuals 
with Rett syndrome and autism for the area and perimeter when measuring the microglia 
soma in the molecular layer, as shown in Figure 7. In addition, the Feret max is 
significantly (p=0.012, two tailed t-test) larger in the autistics, which indicates that the 
soma is longer in its principal axis than that of the controls. For the molecular layer, the 
microglia somas are larger and more irregular in autistic individuals compared to the 
controls. In the granule cell layer there is no difference in the microglial soma comparing 
the autistics and controls. The individuals with Rett syndrome have a significantly larger 
microglia area (p=0.0076, two tailed t-test) compared to the controls in the granule cell 
layer.  
[Figure 7 Top]  
There are more microglia in the molecular layer in individuals with autism and 
the area and perimeter of the microglia somas are larger and more irregularly shaped 
compared to the controls. However, in the granule layer there is no significant difference, 
comparing individuals with autism and controls, in microglia density and morphometry. 
The increase in microglia densities in the cerebellum is specific to the molecular layer, 
which is the location of vast numbers of synapses on Purkinje dendrites.  
There was a significant (p=0.024, two tailed t-test) decrease in the Purkinje cell 
linear density in the vermis of individuals with autism (n=7) with an average of 8.11 
Purkinje cells per mm compared to controls (n=10) with an average of 10.21 Purkinje 
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cells per mm, as shown in Figure 8. This result is specific to the cerebellar vermis, as 
there is no significant difference for the Purkinje cell linear measurement in the lateral 
cerebellum when comparing controls (11.16 Purkinje cells per mm) and individuals with 
autism (10.22 Purkinje cells per mm.) Within the cerebellar cortex in individuals with 
autism, the linear density of Purkinje cells was significantly lower (p=0.017, two tailed t- 
test) in the vermis (8.11 Purkinje cells per mm) than in the lateral cerebellum (10.22 
Purkinje cells per mm). Figure 9 exhibits the average per case represented as a single data 
point for the Purkinje cell linear measurements in the vermis. There were no significant 
differences between the individuals with Rett syndrome compared to the individuals with 
autism and to the neurotypical subjects. In the individual with Joubert syndrome, the 
Purkinje cell density was comparable to the high end of the controls. The Purkinje cell 
linear density in the sibling of an individual with autism was similar to the density in 
individuals with autism for the vermis.  
[Figure 8 Top]  
[Figure 9 Top]  
For the Purkinje cell morphometry, there was no difference for the perimeter and 
area between the autistic and control cases but there was a significant difference for a 
number of measures, which all describe the Purkinje cells as rounder in people with 
autism, as shown in Table 4.  
There were no significant differences in the granule cell densities in individuals 
with autism, Rett syndrome or controls. There was no correlation for the microglial cell 
counts and Purkinje cell counts in the cases with autism, Rett syndrome and controls. For 
the individuals with autism, none of the ADI-R scores correlated with the cell counts or 
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cell morphometry measurements. Finally, the confounds in the cases with autism did not 
account for the differences in the microglial density measures, the Purkinje cell counts, 
granule cell counts and the shape analysis for the microglia and Purkinje cells.  
The important findings of this study include an increase in the microglia density 
in individuals with autism and Rett syndrome specific to the molecular layer in the 
cerebellum, which is the region of the Purkinje and parallel fiber synapses. Moreover, we 
report that not only is there an increase in the microglia density in the molecular layer, 
but that the microglial cells are larger in perimeter and area in individuals with autism 
spectrum disorder compared to controls, which indicates the microglia are in a different 
state. In addition, we found that the individual with Angelman syndrome and the 
individual whose sibling had autism exhibited similar microglia densities in the 
molecular layer as individuals with Rett syndrome and autism spectrum disorder. We also 
found a specific and significant decrease in the Purkinje cells in the vermis of individuals 
with autism compared to controls. Together, these data provide evidence for 
neuropathological and neuroinflammation alterations in individuals with autism spectrum 
disorder.  
Discussion  
Microglia and Neuroinflammation  
Our group is the first to report a significant increase in microglia densities and 
larger microglia somas that are specific to the molecular layer of the cerebellar cortex in 
individuals with autism and Rett syndrome compared to controls. The specific increase of 
microglia density in the molecular layer, which is largely comprised of parallel fiber 
axons synapsing on Purkinje cell dendrites, has several implications for the role of 
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inflammation in the neuropathology in the cerebellum of individuals with autism, which 
will be discussed below. The lack of differences in granule cell density and in microglia 
density in the granule cell layer of the subjects with autism compared to controls are 
additional lines of evidence suggesting that the abnormalities are particularly localized to 
the molecular layer of the cerebellum in autism.  
Vargas et al. (2005) were the first to report an increase in microglia in the 
cerebellar cortex in individuals with autism compared to controls, but their methods and 
results differ from ours in several respects. In Vargas’ analysis, the group used the 
antibody HLA-DR to stain the microglia and measured the microglia with an area 
fraction quantification method based on the Delesse sampling procedure (Gundersen et 
al. 1988). In the area fraction quantification method, the fraction of a two-dimensional 
area covered by a specific cell type is measured, but the method does not provide a three- 
dimensional volume density. In contrast, we quantified IBA1 immunostained microglia in 
separate determinations for the molecular and granule cell layers using the optical 
fractionator method, which provided volume densities for these layers. Despite these 
differences, both studies point to an increase of microglia in the cerebellar cortex in  
individuals with autism. These findings elucidate the neuropathology of the cerebellum in 
autism and suggest that a better understanding of the role of the inflammation in the 
cerebellum could aid in the understanding the behaviors in autism.  
We also found that the microglia somas were larger in the individuals with autism 
and Rett syndrome suggesting that the microglia were in the activated state. Kozlowski 
and Weimer (2012) used the method of automated image analysis to study the 
morphology of fluorescently labeled microglia in mice, which had been challenged with a 
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standard method for inducing microglial activation. The method involved intravenous 
injections of lipopolysaccharide (LPS), an inflammatory agent from the outer cell wall of 
bacteria. Kozlowski and Weimer observed a 23% increase in the size of microglia 
following injections of 1 milligram of LPS per kilogram of body weight after 24 hours. 
This result is close to the increased size we observed in autistic (20.6%) and Rett (19.6%) 
microglia compared to controls. Thus, the increased microglia sizes in autistic and Rett 
syndrome microglia are comparable to those obtained in experimental microglial 
activation with the standard LPS protocol for inflammatory challenge suggesting that the 
microglia may be continuously activated in these conditions. It should be noted, however, 
that in the mice challenged with LPS and in the individuals with autism and Rett 
syndrome, there is considerable variance in the sizes and therefore presumably the 
activation states of individual cells in their microglial populations.  
We are able to directly compare microglia density measures in the cerebral cortex 
and in the cerebellar cortex since we used the same stereological method and many of the 
same individuals in the prior study (Table 3). In our previous study we found on average 
an increase of 20% in microglia density in the cortex in individuals with autism compared 
to controls whereas in the molecular layer of the cerebellar cortex there is a 69% increase 
in the microglia in individuals with autism compared to controls. Thus there are increased 
densities in both the cerebral and cerebellar cortices, but the magnitude of the effect is 
about 3.5 times greater in the cerebellum. Suzuki et al. (2013) measured the microglia 
activation in living individuals with autism using positron emission tomography and 
radiotracer for microglia—[11C](R)-(1-[2-chrorophynyl]- N-methyl- N-[1- 
methylpropyl]-3 isoquinoline carboxamide) ([11C](R)-PK11195)M and found increase of 
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binding potentials in several brain regions in individuals with autism compared to 
neurotypical subjects. The cerebellum, together with the brainstem and orbitofrontal 
cortex, showed the greatest increases in microglial binding in their study. Thus the 
increases in microglia size and/or activity in the cerebellum have been demonstrated for 
subjects with autism by two very different methods.  
These observations lead to the following questions. Why is there an increase in 
microglia density in the brains of individuals with autism? Is the increase in microglia 
neuroprotective or deleterious in the individuals with autism? What is the relationship 
between the microglia and neurocircuitry?  
Microglia are known to become activated due to infection, traumatic brain injury, 
stroke and neurodegenerative diseases; microglia in the quiescent stage are actively 
monitoring their environment and then upon activation engulf and eliminate debris in the 
phagocytic phase (Lin and Bergles, 2004, Vargas et al. 2005, Wake et al. 2009). The 
pioneering studies of Davalos (2005) and Nimmerjahn (2005) showed, using the method 
of in vivo imaging of microglia, that quiescent microglia on a minute-to-minute basis 
constantly probe their environment in the healthy mouse cerebral cortex, which laid the 
foundation for studies to understand the function of microglia in the healthy brain. 
Microglia are known to respond to a number of neurotransmitters, including GABA, 
glutamate, and dopamine, where excitatory neurotransmission has been shown to increase 
microglial process motility and inhibitory neurotransmission-reduced microglia 
movement (Barger and Basile, 2001, Nimmerjahn et al. 2005, Grinberg et al. 2011). 
Using live two-photon imaging of fluorescently labeled microglia and neurons, microglia 
processes make brief (5 min.) and direct contact with synapses in the resting state, and 
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after transient brain ischemia the microglia make prolonged (1 hr.) contact with the 
synapses, often with a receding bouton (Wake et al. 2009). Using the unique feature of 
postnatal development of the visual system and high resolution imaging of microglia, 
investigators report that during the peak critical period (P28), microglia in layer II and VI 
contacted spines, synaptic terminals and synaptic clefts within the visual cortex upon 
visual stimulation (Tremblay et al. 2010).  
Microglia are essential for the normal development of the brain. Microglia sculpt 
the population of Purkinje cells in the normally developing cerebellum (Marin-Teva et al. 
2004). Paolicelli (2011) reported that microglia actively engulf synaptic components and 
are essential for synaptic pruning in the development of the normal mouse brain 
(Paolicelli et al. 2011). Microglia are also essential for the synapse elimination and 
pruning that occur in the normal development of the retino-geniculate pathway in mice 
(Schafer et al, 2012). Microglia are necessary for the masculinization of the male mouse 
brain and behavior, where the microglia are activated in the hypothalamic preoptic area 
(POA) of the male brain and promote the formation of more numerous spines than are 
present in the POA in females (Lenz et al. 2013). These findings demonstrate evidence 
that microglia are active in the healthy brain and function as a key player in normal 
development of neural circuits through synaptic growth and pruning, axon guidance and 
apoptosis.  
Maternal infection increases the risk of neurodevelopmental disorders, 
specifically autism (Atladóttir et al, 2010, Brown and Patterson, 2011). A mouse model 
of maternal immune activation using a poly (I:C) injection on embryonic day 9.5 and/or 
12.5 reported a deficit in the linear density of Purkinje cells specific to lobule VII of the 
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cerebellum and indicates the alteration of the Purkinje cells is caused by maternal 
activation of the immune system occurring during embryonic development (Shi et al. 
2009). A recent study describes that valproic acid, a common pharmaceutical drug used 
to treat epilepsy, has been significantly associated with an increase in autism spectrum 
disorder, even after adjusting for maternal epilepsy (Christensen et al. 2013). An in vitro 
study of primary adult human microglia found that valproic acid reduced the phagocytic 
activity of microglia and the expression of microglial markers (Gibbons et al. 2011). 
Nasu-Hakola disease is a dementia caused by a defect in the TREM2 or DAP12 gene 
which forms a receptor complex and is strongly expressed in microglia (Paloneva et al. 
2002; Sessa et al. 2004). This genetic defect reduces the phagocytic activity of the 
microglia, impairs the clearance of debris in the cortex and induces deficits in social 
behavior as an early manifestation of Nasu-Hakola dementia (Bianchin et al. 2004; 
Neumann and Takahashi 2007). Mutations of TREM2 are also found in a subset of 
patients with late onset Alzheimer’s disease (Jonsson et al, 2013; Guerreiro et al, 2013). 
These data support the hypothesis that suppressing microglial phagocytosis can alter 
brain development and lead to neurodegeneration later in life. Future studies focused on 
understanding the microglial phagocytic activity could have numerous benefits for 
understanding neurodevelopmental and neurodegenerative disorders.  
Purkinje Cells  
We also report a reduction in the Purkinje cell linear density in the vermis of 
individuals with autism compared to vermis in controls and to the lateral cerebellum in 
individuals with autism. In Table 5, we show the previous work for the Purkinje cell 
qualitative and quantitative reports for individuals with autism and Rett, Angelman and 
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Joubert syndromes, which we investigated because subjects with these disorders often 
exhibit the behavioral features of autism. It is also been reported that individuals with 
Rett syndrome exhibit reductions in Purkinje cells; however, we did not observe a 
reduction in the three individuals in our study.  
Exciting new research using a genetic mouse model of Rett syndrome, the 
MECP2 knockout, produces behavioral and synaptic phenotypes similar to autism (Chen 
et al. 2001, Guy et al. 2001). Investigators reported that replenishing a MECP2-knockout 
with wild-type microglia reduced a number of behavioral and physiological deficits and 
restored normal lifespan (Derecki et al. 2012). The authors report that following bone 
marrow transplants carrying normal MECP2 gene into MECP2 knockout mice, 43% of 
the cerebellar microglia are derived from the wildtype, which is a much higher fraction 
than engrafts to other brain structures, especially to the neocortex, where it was only 5% 
(Derecki et al. 2012). This preferential engrafting to the cerebellum implies that that the 
engrafted wildtype microglial in the cerebellum may be largely responsible for the 
restorative effects of the transplants (Derecki et al. 2012). In addition, the benefits 
mediated by wild type microglia were diminished when their phagocytic activity was 
inhibited pharmacologically by using annexin V to block phosphatidylserine residues on 
apoptotic targets preventing recognition and engulfment by tissue resident phagocytes  
(Derecki et al. 2012). These results imply that the phagocytic activity is beneficial in Rett 
syndrome. The MECP2-null mouse provides a remarkable insight into the 
neuropathology of autism spectrum disorder and serves as a guide for future 
investigations to understand the relationship between the microglia and neurons in the 
cerebellum.  
 
67
	  
The individual with Angelman syndrome we investigated had a deletion on 
chromosome 15 Q. 2Q 13, which most often is the ubiquitin E3 ligase (UBE3A) gene. 
The microglia density in the molecular layer of the individual with Angelman syndrome 
was higher than any of the individuals with autism; the Purkinje cell density was in the 
autistic range. The histology of the brain in individuals with Angelman syndrome has 
been reported for only one case in the literature and this was qualitatively normal with 
respect to the cerebellar cortex (Kyriakides et al. 1992). In mice, the maternal copy of 
UBE3A is strongly expressed in Purkinje cells and the paternal copy of UBE3A is hardly 
expressed at all in the cerebellum (Dindot et al. 2008). In normal mice, the maternal copy 
of UBE3A is weakly expressed in the granule cells or in the molecular layer, which 
included the microglia; therefore the direct action of the genetic defect in the cerebellum 
of individuals with Angelman syndrome is in the Purkinje cells and not in the granule 
cells or microglia. The UBE3A knockout in mice has no effect on the density the 
Purkinje cell somas or the branching pattern of the Purkinje dendrites; however there was 
a reduction in the spine density on the Purkinje cells (Dindot et al. 2008). The primary 
defect in the UBE3A maternal knockout in the cerebellum was a reduction in the spine 
density on the dendrites of the Purkinje cells (Dindot et al. 2008). These results suggest 
that the increased microglia density we observed in the molecular layer of individuals 
with Angelman syndrome might be secondary to defects in the Purkinje cells’ spines. 
This mechanism in Angelman syndrome is important to understand for a more 
comprehensive approach to the mechanism of autism and the UBE3A provides an 
excellent mouse model to study autism spectrum disorder in future investigations. There 
are also significant enrichments in copy number variations for UBE3A in genome-wide 
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association studies of individuals with autism compared to controls (Glessner et al, 2009; 
Bucan et al, 2009), which further implicates this gene in autism.  
In addition, we studied the cerebellum of an individual with Joubert syndrome. 
Joubert syndrome is a rare genetic disorder, which can be caused by mutations of more 
than 20 genes which effect cerebellar development. In particular, it is characterized by an 
underdevelopment of the cerebellar vermis and malformed brainstem (Joubert et al. 
1969). This case comparison was valuable since there are reports of hypoplasia of the 
vermis in individuals with autism, which was specifically true in this individual case 
(Courchesne et al. 1988, Scott et al. 2009). The previous histological reports for Joubert 
syndrome include only four individuals and describe mixed results in the neuropathology. 
In the original report of Joubert syndrome, the authors described no reduction in Purkinje 
cells and an increase in the astrocytes in the molecular layer (Joubert et al. 1969). Three 
more recent individual case reports found reduced Purkinje cells in the individuals with 
Joubert syndrome and increases in astroglia but none of the studies analyzed the 
microglia (Ishikawa, et al. 2008; Maria, 1999; Yachnis and Rorke 1999). The microglia 
densities in the individual with Joubert syndrome in our study were exceptionally low in 
the molecular layer, lower in fact than in any of the controls, which differs markedly 
from the individuals with autism, Rett syndrome and Angelman syndrome. By contrast, 
the Purkinje cell densities in the individual with Joubert syndrome are in the high normal 
range. Although we only studied a single individual with Joubert syndrome, these 
differences in the neuropathology suggest that this neurodevelopmental disorder is 
distinct from the other conditions. In addition, this shows that having a specific defect in 
the development of the vermis does not lead to increased microglial densities, and that 
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different pathobiological mechanisms are involved in autism, and in Rett and Angelman 
syndromes. This finding also suggests that neuroinflammation in the molecular layer of 
the cerebellum in autism, Rett syndrome, and Angelman syndrome may be specific to the 
pruning and plasticity of the Purkinje cell dendrites in multiple cerebellar regions 
including the vermis and lateral cerebellum.  
Purkinje cells are the only efferent neurons from the cerebellar cortex; in the 
mouse cerebellum there are about 175,000 parallel fiber synapses on an individual 
Purkinje cell dendritic tree (Napper and Harvey, 1998). Long term depression (LTD) in 
activity at the parallel fiber-Purkinje cell synapses is the main mechanism for the 
Purkinje cell plasticity and is the mechanism necessary for the eye blink conditioning, 
which is a form of learning that is dependent on the cerebellum (Ito 1986). LTD lasts 
only a few hours and a major question has been how the transient change is translated 
into a long-term change in synaptic connectivity (Ito 2012). In view of the capacity of 
microglia to monitor and alter synapses, it is possible that these cells have a role in 
converting the synaptic modifications in LTD into long-term structural changes in 
connectivity. There is a report of an increase in the dendritic spines of individuals with 
autism in the cerebral cortex using the Golgi method (Hutsler and Zhang 2009). 
Extensive investigation of the dendritic spines in the cerebellar cortex of individuals with 
autism would provide a greater understanding for the relationship between the Purkinje 
cells and the microglia. Perhaps the selective increases in microglial density in autism, 
Rett and Angelman syndromes in the synapse-rich molecular layer might reflect a 
dysfunction in this learning-related process in these conditions.  
The Cerebellum in Autism  
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A number of reports indicate that cerebellar hypoplasia is a feature of autism 
(Courchesne et al. 1997, Scott, et al. 2009, Bolduc, et al. 2011). Using magnetic 
resonance imaging (MRI), Courchesne reported that the cerebellar vermal lobules 6 and 7  
were significantly smaller in patients with autism and described it to be a result of 
developmental hypoplasia rather than shrinkage or deterioration after full development of 
the individuals (Courchesne et al. 1988). By contrast, in an MRI study of the cerebellum 
that included 35 individuals with autism and age matched controls, no abnormalities in 
cerebellar lobules 6 and 7 in autistic individuals were detected, but the volume of the total 
cerebellum was significantly increased in individuals with autism (Piven, et al. 1997). 
The authors proposed that their finding differed from Courchesne and colleagues because 
Courchesne did not match for IQs between the individuals with autism and controls 
(Piven, et al. 1997). A recent MRI study of individuals with various autism spectrum 
disorders found that the mid-sagittal area of the vermis was decreased specifically to the 
high-functioning autism group compared to controls and that neither IQ nor age predicted 
the size of the vermis within the various autism groups. (Scott, et al. 2009). In addition, 
these authors found that the total volume of the vermis was decreased across the 
combined group of all individuals with ASD (Scott, et al. 2009). A more recent study 
identified decreases in vermis volume correlated with global impairments in 
development, cognition, expressive language, fine and gross motor skills, and behavior 
problems, as well as a higher rate of positive testing for ASD (Bolduc, et al. 2011). The 
largest MRI study to date, based 89 individuals with autism spectrum disorder and 
controls, observed that the neuroanatomic networks correlated with ASD included the 
cerebellum (Ecker et al. 2012). The most recent MRI analysis of the cerebellum for 
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individuals with autism reports that there is a specific reduction in the grey matter of the 
vermis and CRUS-II in low functioning individuals with autism and it is associated with 
social and interaction deficits in ASD (Riva et al. 2013). In an early MRI study, 
investigators reported a progressive cerebellar atrophy increasing in age in individuals 
with Rett syndrome in contrast to individuals with autism (Murakami et al. 1992).  
Numerous reports provide evidence that individuals with autism exhibit motor deficits in 
addition to the classical symptoms of autism (Vilensky et al. 1981, Green et al. 2009). 
Subjects with autism display in gait disturbances indicating a specific dysfunction in the 
motor system (Vilensky et al. 1981). It is reported that autistic children often have a 
variety of postural instabilities, greater clumsiness, and altered motor coordination 
(Bauman and Kemper 2005, Molloy et al. 2003). In a recent study designed to understand 
the relationship of motor coordination deficits in autism, the investigators identified 83 
studies that focused on motor coordination, arm movement, gait, and postural instability 
deficits in autism, and reported that individuals with autism had substantial motor 
coordination deficits across a wide range of behaviors, and described motor abnormalities 
as a cardinal feature of autism (Fournier et al. 2010). More importantly, these are 
additional lines of evidence that the cerebellum is altered in autism and that not only do 
the motor dysfunctions account for the cerebellar alterations but the cognitive and social 
deficits in autism can be addressed by the cerebellar abnormalities. Cerebellar lesions are 
involved in several neuropsychological behaviors including impairments in language, 
executive functions, mood and affect (Schmahmann & Sherman, 1997). In a study 
reviewing the developmental malformations of the cerebellum, vermis malformations 
induced affective and social disorders and were more associated with autism spectrum 
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symptoms (Tavano et al. 2007). In particular, the cerebellum is described as a common 
site for altered connectivity in individuals with autism (Belmonte et al. 2004). There have 
been a number of functional neuroimaging studies that have shown activation for several 
non-motor tasks (Gao et al. 1996). Buckner’s massive study on the functional 
connectivity of the cerebellum based on one thousand subjects reported that the 
cerebellum contains at least two large, homotopic maps of the entire neocortex (Buckner 
et al. 2011). In particular, the prefrontal cortex and Broca’s area are over-represented in 
the cerebellar cortex whereas the somato-motor cortex is underrepresented in the 
cerebellar cortex (Buckner et al. 2011). A recent study explains that the cerebellum 
operates as a general co-processor, whose outcome is dependent on the connectivity of 
brain regions, impacting cognitive functions, sensory and motor processing (D’Angelo et 
al. 2012). Kawato et al. (1987) described the concept of a “forward model” which is a 
feedback-optimized program for the manipulation of a controlled object where a robust 
model provides smooth motor performance based on experience (Ito 2012). This concept 
of a forward model could be applied to the cerebellum for learning different social cues 
and behaviors and if there is a disruption in the forward model the appropriate behaviors 
would not be efficiently learned and the responses would then become difficult and 
effortful. Describing a patient with a unilateral cerebellar lesion, Holmes (1939) wrote: 
“One intelligent and observant patient remarked, ‘The movements of my left arm are 
done subconsciously, but I have to think out each movement of the right (affected) arm. I 
come to a dead stop in turning and have to think before I start again.’ It is significant that 
practice may improve the performance of the test.” This highlights the process of a 
disrupted cerebellar forward model where the patient described a contrast between the 
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unaffected arm performing the task as an automatic response and the affected arm 
required effortful concentration on the task due to the cerebellar lesion. 
Temple Grandin, as a person with autism, commented (Grandin, 2005): “Each 
day, I collect more data to place in my library of experience. When I encounter a new 
social situation, I have to search my memory for a similar experience that I can use as a 
model for my next action. As I fill my database with more and more information, I 
become better and better at handling different social situations. I have to rehearse how to 
deal with a person before I interact with him or her. I have a very difficult time when I 
am confronted with unexpected social surprises. For common social interactions with 
clients, I use programmed, prerehearsed responses. Everything is done with logic.” Her 
very insightful description of her difficulties with social interactions and her reliance on 
conscious effortful processing may serve as a powerful illustration of the limitations of  
not having an effective forward model for social interactions. Together these data 
describe the importance of the cerebellar connectivity for cognitive, behavioral, sensory, 
and motor processing in individuals with autism. In particular, a primary alteration in the 
Purkinje cell layer and neuroinflammation in the molecular layer containing the Purkinje 
cell synapses could disrupt the critical connectivity for processing cognitive, sensory and 
motor behaviors in individuals with autism.  
Conclusion  
We report an increase in the microglia density in the molecular layer of the 
cerebellum, the location of the Purkinje synapse dendrites, in individuals with autism, 
Rett and Angelman syndromes, which may be the key to understanding these 
neurodevelopmental disorders. In particular the increase in microglial density in the 
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molecular layer is another line of evidence for neuroinflammation in autism. Perhaps the 
capacity of microglia to monitor and alter synapses in the cerebellum could be a 
mechanism for converting the synaptic modifications in LTD into long-term structural 
changes in connectivity. A detailed examination of the dendritic spines of the Purkinje 
cells in the cerebellar cortex of individuals with autism would provide a greater 
understanding of the relationship between the Purkinje dendritic spines, connectivity and 
microglia function and modification. Moreover, these findings support the utility of the 
MECP2 and UBE3A knockout mice since the neuropathology in the human Rett and 
Angelman subjects was similar to that of individuals with autism. Both the MECP2 and 
the UBE3A mice are excellent models for exploring the relationship between 
neuroinflammation and neuronal circuits in the brain. Importantly, answering the 
question of whether the inflammation is harmful or beneficial would be a great advance 
in understanding the pathology in autism and could provide possible therapeutics. In 
addition, these findings support the hypothesis that the cerebellar neuropathology is a 
core feature in autism and accounts for a number of the social impairments, behavioral 
symptoms and motor deficits in individuals with autism. Future studies dedicated to 
cerebellar connectivity in autism could provide advancement in understanding autism. 
The utility of the networks involved in the cerebellar forward model for cognition, social 
and motor behaviors could aid in a greater understanding of autism spectrum disorders.  
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CHAPTER 4: SUMMARY AND CONCLUSIONS 
In this thesis we describe an increase in microglial densities in the cerebral and 
cerebellar cortices in autism. In our first study, we found an average increase of 20% in 
microglial densities in individuals with autism in fronto-insular cortex and visual cortex, 
two disparate cortical regions, which indicates a global increase in microglia densities in 
subjects with autism compared to neurotypicals (Tetreault et al., 2012). In our second 
study, we examined subjects with a variety of neurodevelopmental disorders, including 
autism, Rett, Angelman, and Joubert syndromes, and a sibling of an autistic individual, to 
determine whether the microglia densities, Purkinje cell linear densities and the 
neuropathological states are specific to any of the disorders. We found a much larger 
elevation in microglia densities (compared to the cerebral cortex) in individuals with 
autism and Rett syndrome, specific to the molecular layer in the cerebellum, which is the 
region of the Purkinje and parallel fiber synapses. In addition, the Angelman syndrome 
case and the sibling of an individual with autism both had microglia densities in the range 
of the individuals with autism and Rett syndrome. By contrast, the Joubert syndrome case 
has a lower density than any of the controls. We also found a significant deficit in the 
Purkinje cells in the vermis of individuals with autism compared to controls. The 
Purkinje cell density in the vermis was also significantly lower than in the lateral 
cerebellum in the autistic subjects indicating that the abnormality is specific to the 
vermis. Together, these data provide evidence for neuropathological and 
neuroinflammation alterations in individuals with autism spectrum disorder. Moreover, 
we report that not only was there an elevation in the microglia density in the molecular 
layer, but that the microglial cells were larger in perimeter and area in individuals with 
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autism spectrum disorder compared to controls, which suggests that the microglia are 
chronically activated in the molecular layer.  
The microglia density in the Joubert’s syndrome case in our study was 
exceptionally low in the molecular layer, lower in fact than any of the controls, which 
differs markedly from the autism, Rett syndrome and Angelman syndrome cases. In 
addition, the average microglia soma was larger in the Joubert case compared to the 
autism and Rett syndrome cases in both the molecular and granule cell layers. These 
findings suggest that the microglia are not different in the granule cell and molecular 
layers of the Joubert case. In addition, this single Joubert case had the largest microglia 
soma size, which suggests that the microglia may have been filled with inclusions and 
may be in the end state of gliosis, which would be consistent with vermal hypoplasia. By 
contrast, the Purkinje cell density in the Joubert syndrome case was in the high normal 
range. Although we only studied this single case, these differences in the neuropathology 
suggest that this neurodevelopmental disorder is distinct from the other conditions. In 
addition, the Joubert findings show that having a specific defect in the vermis does not 
necessarily lead to increased microglial densities, and that different pathobiological 
mechanisms are likely to be involved in this condition compared to autism, Rett and 
Angelman syndromes.  
Since microglial density is significantly elevated across all the disorders (except 
Joubert syndrome) compared to neurotypicals, it appears that the increase in microglia 
density is not specific to autism spectrum disorder but rather is a feature common to a 
number of developmental disorders. However, microglia in individuals with autism and 
Rett syndrome have an increased soma size, suggesting a chronically activated state, 
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which could indicate possible environmental factors, perhaps in combination with genetic 
predisposition, leading to a systemic infection or an alteration in the phagocytic function 
of the microglia. There are several other lines of evidence for an elevated state of 
inflammation in individuals with autism. There are several reports of an elevated 
cytokines in the cerebral spinal fluid in individuals with autism as compared to 
neurotypicals (Vargas et al., 2005; Zimmerman et al., 2005; Chez et al., 2007). 
Individuals with autism also show a significantly elevated expression of C-reactive 
protein (CRP), indicative of an inflammatory response, and there is a positive correlation 
between CRP and the severity of autism (Khakzad et al., 2012). A recent study in 
Finland, including a national cohort of over a million samples of prenatal sera measuring 
the level of CRP, indicates there is a significant association between elevated levels in the 
mother’s serum and  the likelihood that her child will become autistic (Brown et al., 
2013). For the maternal CRP levels in the highest quintile compared to the lowest 
quintile, there is a significant, 43% elevated risk for autism (Brown et al., 2013).  
Maternal infection and immune activation are also associated with autism (Brown 
et al., 2004, Patterson et al., 2012). In a model of maternal immune activation (MAI) in 
which the viral mimic polyinosine:cytosine (poly(I:C)) is injected in pregnant mice, the 
offspring exhibit autism-like behaviors, with deficits in social interaction, verbal and 
olfactory communication and prepulse inhibition, elevated stereotyped/repetitive 
behaviors, as well as a deficit in cerebellar Purkinje cells (Shi et al., 2009; Malkova et al., 
2012). In addition, Hsiao et al., (2012) report that MIA increases interleukin-6 (IL-6) in 
the placenta and fetal brain, which reduces placental growth hormone, possibly causing 
harmful effects on fetal brain development. A recent examination of metabolic 
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conditions, such as diabetes, hypertension and obesity during pregnancy and their 
association with autism, reported that mothers with obesity were 1.6 times more likely to 
have a child with autism spectrum disorder (Krakowiak et al., 2012). In obesity there are 
increases in proinflammatory cytokines: specifically, there are elevated levels of IL-6 and 
TNF-alpha which can alter fetal development (Krakowiak et al., 2012).  
Thus, there are a number of maternal risk factors that are associated with 
increased incidence of autism in the offspring. Using a model of peripheral organ 
inflammation, cerebral microglia recruit monocytes into the brain through the release of 
TNF-alpha (D’Mello et al., 2009). It is possible that systemic infection leads to elevated 
levels of microglia in individuals with autism. These data highlight that there is an 
elevation of systemic inflammation and it is plausible that maternal inflammation is a risk 
factor, which can lead to chronic neuroinflammation and increased microglia density in 
autism.  
Another potential mechanism for the increase of microglia density in autism and 
Rett syndrome is an alteration in the phagocytic function of the microglial cells. 
Introducing into MECP2-knockout mice wild-type microglia via bone marrow 
transplantation reduces a number of behavioral and physiological deficits and restores 
normal lifespan in this mouse model with autistic features (Derecki et al., 2012). The 
transplanted wild-type microglia were far more likely to take up residence in the 
cerebellum than in the cerebral cortex in these mice, which indicates that these cerebellar 
microglia play a large role in the restoration of function in these animals (Derecki et al., 
2012). It is notable that the benefits of wild-type microglia diminished when their 
phagocytic activity was inhibited using annexin V to block phosphatidylserine residues 
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on apoptotic targets, which prevents recognition and engulfment by phagocytes  (Derecki 
et al., 2012). These results imply that the phagocytic activity of the transplanted microglia 
is central to the restorative effect and that impaired microglial phagocytosis may be 
crucial to Rett syndrome. Therefore, the elevated microglial density in the autism and 
Rett syndrome cases could be due to a compensation for dysfunction in the microglial 
phagocytic activity. Maternal use of valproic acid, a drug used to treat epilepsy, is 
significantly associated with an increase in autism spectrum disorder in the offspring 
(Christensen et al., 2013). Consistent with the hypothesis that autism may arise from 
impaired microglial phagocytosis, valproic acid reduces the phagocytic activity of 
primary, adult human microglia and the expression of microglial markers in vitro 
(Gibbons et al., 2011). 
There is additional evidence that impaired microglia phagocytosis is the cause of 
neurological diseases. Nasu-Hakola dementia is caused by a defect in the TREM2 or 
DAP12 genes, whose proteins form a receptor complex that is strongly expressed in 
microglia (Paloneva et al., 2002; Sessa et al., 2004). This genetic defect reduces the 
phagocytic activity of microglia, impairs the clearance of debris in the cortex and induces 
deficits in social behavior as an early manifestation of Nasu-Hakola dementia (Bianchin 
et al., 2004; Neumann and Takahashi 2007). Mutations of TREM2 are also found in a 
subset of patients with late onset Alzheimer’s disease (Jonsson et al., 2013; Guerreiro et 
al., 2013). In a more recent study of Alzheimer’s disease, the CD33 susceptibility loci 
that are risk factors for Alzheimer's disease are linked to defective microglia 
phagocytosis of amyloid and result in increased numbers of microglia in the brains of 
individuals with the susceptibility loci (Bradshaw et al., 2013).  
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       The passage of macrophages from the blood into the brain may also be impeded in 
autism. Individuals with autism exhibit reduced levels of soluble platelet endothelial 
molecule-1 and p-selectin, both of which facilitate leukocyte migration and blood brain 
barrier permeability, which could influence macrophages influx into the brain (Onore et 
al., 2012). This, in turn, could be another defect where healthy microglia cannot aid in the 
dysfunction and leads to an alteration in phagocytic activity, and elevated dysfunctional 
microglia in individuals with autism.  
These data support the hypothesis that suppressing microglial phagocytosis can 
alter brain development and lead to neurodegeneration later in life. Future studies focused 
on understanding the microglial phagocytic activity could have numerous benefits for 
understanding neurodevelopmental and neurodegenerative disorders.  
It is interesting that the Angelman case had an elevated microglial density similar 
to the autism and Rett syndrome cases, but the microglial soma size in Angelman 
syndrome was in the range of the neurotypicals. These findings suggest that there are 
more microglia but they may not be chronically activated in Angelman syndrome. As 
described earlier, knocking out the maternal copy of  UBE3A in mice has no effect on the 
density of the Purkinje cell somas or the branching pattern of the Purkinje dendrites; 
however there was a reduction in the spine density on the Purkinje cells (Dindot et al., 
2008). Since UBE3A is strongly expressed in the Purkinje cells but hardly expressed in 
other cell types in the cerebellum (Dinot et al., 2008; Allen Brain Atlas), it is likely that 
the defect arises from an abnormality within the Purkinje cells themselves and may be  
related to the mechanisms of long term depression (LTD) which will be discussed below. 
The mouse model of Angelman syndrome had impaired learning, fear conditioning, and 
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motor deficits (Huang et al., 2013). Increasing the number of UBE3A gene copies is also 
linked to autism, and increasing the UBE3A gene in the mouse threefold results in mice 
that exhibit the core autism behaviors including defective social interaction, impaired 
communication and increased stereotypic behaviors as well as altered gluatamatergic 
synaptic transmission, resulting in reduced excitatory transmission (Smith et al., 2011). 
Experience-driven neural activity generates UBE3A transcription, in which UBE3A 
alters excitatory synapse development by reducing the number of  the AMPA receptors at 
excitatory synapses (Greer et al., 2010). Thus, the reduction in the glutamate receptors in 
the Angelman mice could explain the reduction of the dendritic spines on the Purkinje 
cells. In the Angelman syndrome individual, the increased density of microglia could 
have been a response to the need for increased synaptic pruning due to defective parallel 
fiber-Purkinje cell synapses. The overexpression of UBE3A in some individuals with 
autism and the mouse model of this condition might also impair these synapses.  
Microglia make contact with synapses at a frequency dependent on the activity of 
the neurons (Wake et al., 2009). In a model of neuronal degeneration, microglia contact 
synapses more frequently and actively remove synapses of degenerating cells (Wake et 
al., 2009). In particular, the increase in microglia density could be related to the reduced 
number of dendritic spines on the Purkinje cells through the mechanism of long-term 
depression (LTD). LTD of the Purkinje synapses lasts only a few hours and a major 
question has been how the transient change is translated into a long-term change in 
synaptic connectivity (Ito, 2012). In view of the capacity of microglia to monitor and 
alter synapses, these cells might have a role in converting the synaptic modifications in 
LTD into long-term structural changes in connectivity. Interestingly, the UBE3A materal 
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knockout in the mouse model of Angelman syndrome reduces LTD in the visual cortex of 
mice (Yashiro et al., 2009). UBE3A expression is linked to the presence of the AMPA 
glutamate receptors at the synaptic interface (Greer et al., 2010), and LTD at the parallel 
fiber-Purkinje cell synapses appears to depend on the reduction in the number of AMPA 
receptors (Ogasawara et al., 2008). Thus the maternal UBE3A knockout in Angelman 
syndrome may impair LTD. Future studies of two-photon imaging of microglia and 
Purkinje cells could advance the understanding of the relationship of neuron-microglia 
interaction in the normal state, and in addition illuminate the mechanisms for synapse 
elimination and possibly the elevated microglia densities in Angelman syndrome.  
The sibling of an individual with autism had an elevated microglia density and 
increased microglia soma size, which were similar to autism cases. This individual was a 
twenty-two-year-old male and a member of a set of triplets in which another member had 
been diagnosed with autism. The sibling case tested for autism, but did not meet the 
diagnostic criteria. He lacked normal eye contact, had social awkwardness, exhibited 
stereotyped nervous behaviors and felt socially isolated. He met the diagnostic criteria for 
obsessive-compulsive disorder (OCD) and social anxiety disorder but not for major 
depressive disorder. However, his death was a suicide. Elevated rates of both major 
depression and social phobia are found among parents and siblings in the families with an 
autistic child (Smalley et al., 1995). Since this individual had elevated microglia density 
and soma size similar to the autism cases, this suggests that the microglia changes could 
be relevant for social anxiety and OCD.  
Is elevated of microglia density in autism a biomarker for the disorder? 
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Although this study examined ten autistic cases, it will be necessary to evaluate many 
more autism brains, because of the heterogeneity in neuropathological observations and 
specifically in microglia pathology. Second, even though microglia density is elevated in 
the cerebral and cerebellar cortex in autism (Vargas et al., 2005; Morgan et al., 2011, 
Tetreault et al., 2012), we have evidence for an increase in microglial density in both Rett 
and Angelman syndromes and in the sibling of an autistic individual in the cerebellar 
cortex. This indicates that the elevation of microglia is not specific to autism, but rather, 
it is a common feature of several neurodevelopmental disorders. In addition, there are 
several lines of evidence for increased neuroinflammation and microglia activation in 
mental illnesses including schizophrenia (Bayer et al., 1999; Wierzba-Bobrowicz et al., 
2004), sickness behavior (Perry et. al., 2010) and major depressive disorder 
(Trzonkowski et al., 2004). In general, it appears that elevated microglia and 
neuroinflamamtion is a feature of several neuropsychiatric diseases, but the anatomical 
patterns of increased densities may vary in different disorders.  
Would an anti-inflammatory treatment aid in reducing the symptoms in autism? 
The next logical step would be to treat developmental and psychiatric patients 
with autism using an anti-inflammatory medication. A recent clinical trial of minocycline 
in patients with autism showed no clinical improvements after six months of testing 
(Pardo et al., 2013). This study was a very small case study (N=10) and notably, the 
baseline microglia activation was not measured using imaging techniques. The peripheral 
immune status was not assessed. Ideally, it would be important to know whether the 
individuals are suffering from neuroinflammation prior to the minocycline treatment, 
which can be achieved using positron emission tomography and radiotracer for 
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microglia—[11C](R)-(1-[2-chrorophynyl]- N-methyl- N-[1- methylpropyl]-3 
isoquinoline carboxamide) ([11C](R)-PK11195). Measuring the microglia in vivo would 
provide a baseline and a post treatment measure of the microglia would provide insight 
into whether the minocyline is actually targeting the microglia, which is the main source 
of the neuroinflammation in the brain. Although there was no difference in the clinical 
trials for autism after six months, there are, however, benefits for two minocycline trials 
double blind placebo-controlled in schizophrenia (Levkovitiz et al., 2010; Chaudry et al., 
2012). Both of these studies were performed with large number of participants, 54 and 
114, and reported beneficial effects on cognitive function and negative features of 
schizophrenia with the use of the drug in the early stages of schizophrenia (Levkovitiz et 
al., 2010; Chaudry et al., 2012). In a recent trial testing the an antibody against TNF, a 
proinflammatory cytokine, to treat psoriasis revealed a decrease in depression in major 
depressive disorder, as a side effect and this reduction was unrelated to the decreased 
psoriasis symptoms (Raison & Miller, 2013). It is possible to have another minocycline 
trial in individuals with autism under different conditions, such as including participants 
with early autism diagnosis, measuring the level of activated microglia pre- and post- 
treatment, including greater number of subjects, and testing with double blind placebo-
controlled groups, which may yield better results and may suggest a beneficial 
therapeutic for individuals with autism.  
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Table 1 Individuals examined for microglial densities, Purkinje cell linear measurements and granule cell densities in the cerebellum.  
The tissue source is NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, MD. 
PMI=post-mortem interval.  X=density measurements were made for this structure.   
ID GUID Age Sex Cause of Death Brain Weight PMI section Vermis  
Lateral 
Cerebellum 
Autistic          
M4021 NDAR_INVUX2 3 M drowning 1330g 15 hrs. 4 X X 
M4029 NDAR_INVRX2 3 M drowning 1130g 13 hrs. 4 X X 
UMB5308 NDAR_INVGG735JVA 4 M skull fractures  1310g 21 hrs. 10  X 
UMB4671 NDAR_INVVY9 4 F fall from 9th story 1320g 13 hrs.  X  
UMB797 NDAR_YX624FEY 9 M drowning 1320g 13 hrs.  generic CB  
UMB4305 NDAR_WL137ER1 12 M Serotonin Syndrome  1360g 13 hrs. 2, 10 X X 
UMB4899 NDAR_INVGW5 14 M drowning 1450g 9 hrs. 4 X X 
UMB5278 NDAR_YH540PL 15 F drowning with seizure 1417g 13 hrs. 4 X X 
UMB5294 NDAR_INVYN399YKW 19 M suicide by hanging       1560g 16 hrs.   X 
UMB4999 NDAR_INVVM9 20 M cardiac arrhythmia 1427g 14 hrs. 4 X X 
Sibling of 
Autistic                 
UMB5378 NDAR_INVRP817TM7 22 M suicide by hanging 1500g 8 hrs. 2, 10 X X 
Control          
UMB1791 NDAR_INVXL388UKV 2 F drowning        1200g 12 hrs. 2 X  
UMB1284 NDAR_INVPP10 3 F drowning 1250g 11 hrs. 4 X X 
UMB4670 NDAR_INVEA3 4 M commoito cordis 1470g 17 hrs. 10  X 
UMB1708 NDAR_INVRJ569TT1 8 F compressional asphyxia 1320g 20 hrs. 10  X 
UMB5387 not provided 12 M drowning 1750g 13 hrs. 4 X X 
UMB5077 NDAR_INVFE727ZB7 16 F multiple injuries       1330g 13 hrs. 3 X  
UMB4591 NDAR_INVVH3 16 F multiple injuries 1330g 14 hrs. 4 X X 
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UMB4727 NDAR_INVAD6 20 M multiple injuries 1330g 5 hrs. 4 X X 
UMB1542 NDAR_INVXZ7 22 M multiple injuries 1510g 4 hrs. 4 X X 
Rett          
UMB4882 NDAR_INVFK280UCW 17 F complications of disorder 871g 18 hrs. 4 X  
UMB1815 NDAR_INVVH323KHT 18 F complications of disorder 930g 5 hrs. 4 X  
UMB4516 NDAR_INVJE188DKF 20 F natural 980g 9 hrs. 4 X  
Angelman           
UMB1754 NDAR_INUJ814JV0 4 M drowning 1360g 24 hrs. 8  X 
Joubert          
UMB5486  5 F complication of disorder       1035g    6 hrs. 2, 10 X X 
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Table 2 This table is adapted from Tetreault et al. (2012) and new cases are shown in the table which include individuals with autism, 
the sibling of an autistic, the Rett cases, an Angelman case and a Joubert case.  Below is a phenotypic description of the autistic 
subjects including age, gender, seizure status, medications, medical history, cause of death, PMI, and 1ADI-R (Autism Diagnostic 
Interview-Revised) test description and cutoffs: Qualitative Abnormalities in Social Interaction (A=10), Qualitative Abnormalities in 
Communication (B=7), Stereotyped Patterns (C= 3), and Abnormal Development (D=1).  All subjects have a psychological evaluation 
and a Bayley or a developmental test. 2Minio-Paluello et al, 2009. 3Matson et al, 2008. 4Goldberg et al, 2003. 5Walters et al, 1990.  
6MacDonald et al, 2006. 
Patient ID Age & Gender PMI 
Cause of 
Death 
Seizure 
Disorder Medication 
Additional 
Medical 
Hist. 
ADI-R1 
Neuropath 
Report or  
Autopsy 
Patient Summary 
Respirator or 
Traumatic 
Death State 
Autistics           
M4021 
 
3 years  
Male 
15 
hours drowning no 
none 
reported none reported 
 
none 
reported 
none provided 
Rigid routine, many 
repetitive6 and 
aggressive 
behaviors. No 
gestures for 
communication, 
auditory sensitivity.   
none reported 
M4029 
 
3 years  
Male 
13 
hours drowning no 
none 
reported none reported 
 
none 
reported 
none provided 
Autistic regression4 
at 24 months, 
aggressive 
behaviors, negative 
response to several 
sensory stimuli and 
ran from sounds.   
Found in a 
canal and 
resuscitated 
with CPR.  
Five hours on 
respirator.   
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UMB5308 4 years Male 
21 
hours 
skull fractures 
motor vehicle 
accident 
no none reported none reported 
A: 17 
B: 14 
C: 4 
D: 3 
neuropath; 
moderte 
edema, 
cerebral and 
cerebellar 
hemispheres 
reported 
intact 
Walked at 11 
months, no 
language, only 
babbled and no use 
of words, parallel 
play with others, 
often ignored others, 
no imitation, 
sometimes had eye 
contact, 
inappropriate 
laughing, smiled 
often, avoided large 
groups, lacked social 
cues, followed 
routines, hand 
flapping, head 
banging 
Immediate 
death when 
struck by a 
motor vehicle. 
UMB4671 
 
4 years  
Female 
13 
hours 
fall 
9 stories no 
none 
reported diaper rash 
A: 26 
B:13 
C: 3 
D: 5 
autopsy; 
noted normal 
brain 
Lacked body self 
awareness and 
awareness of others2 
(observed by 
mother); could not 
identify body parts 
when tested by a 
psychologist. 
Normal hearing. 
Cognition delayed; 
no socialization. 
none reported 
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UMB797 
9 
years 
Male 
22 
hours drowning  no Desipramine 
ADHD; 
seizure 
associated 
with 
medication, 
migraines 
A: 24 
B: 20 
C: 6 
D: NA 
neuropath; 
noted normal 
brain 
 
 No hypersensitivity 
to sensory stimuli, 8 
cortical regions 
stained with H&E, 
no microgliosis in 
cortex, VC had 
unusually large 
Meynert cells and an 
irregular  shaped 
claustrum.    
Overdose of 
desipramine a 
week prior to 
death; 
no revival.  
UMB4305 
 
12 years  
Male 
13 
hours 
serotonin 
syndrome yes 
Clonazepam 
Depakote  
Olazapine 
Quetiapine 
 
 
pervasive 
development 
disorder 
NOS 
psychosis 
NOS 
ADHD 
A: 25 
B: 15 
C: 8 
D: 4 
neuropath; 
necrosis 
effects; large 
macrophage 
& astrocytes 
in RH.  
Very aggressive, 
destructive and 
abusive behavior 
without provocation; 
special education, 
lived in group home, 
unmanageable 
behavior.  Lacked 
bladder control. 
Large 
contusion in 
right frontal 
lobe; cystic 
necrosis.    
UMB4899 
 
14 years 
Male 
9 
hours drowning  yes 
Clonidine 
Trileptal 
Zoloft 
 
 
none reported 
A: 22 
B: 14 
C: 8 
D: 4 
neuropath; 
 normal 
brain and  
cortex 
Loss of verbal skills 
at 1 year; high levels 
of sensory interest, 
compulsions and 
stereotypy6.  Autistic 
regression4. 
Found in 
bottom of 
pool, CPR 
revived, on life 
support for 24 
hours.   
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UMB5278 
15 
years  
Female 
13 
hours drowning  yes 
Depakote 
Keppra 
Prozac  
 
none reported 
A: 22 
B: 11 
C: 5 
D: 5 
none 
provided; 
noted normal 
brain 
Noted to have mild 
autism, high 
functioning & at 
grade level, seizures 
from infancy, 
second cousin has 
autism, had 
spontaneous speech 
and aggressive 
behavior.   
none reported 
UMB5294 
 
19 years 
Male 
16 
hours 
suicide by 
hanging no 
Zoloft 
Seroquel 
Welbutrin 
Luvox 
Ritalin 
Refused to 
take 
medications 
prior to death 
Asperger’s 
diagnosis, 
ADD, high 
cholesterol, 
asthma,  
depressed 
mood and 
first cousin 
had autism 
A: 17 
B: 19 
C: 5 
D: 2 
neuropath; 
neurons 
mildly 
reduced & 
contracted in 
cerebellum, 
mild WM 
edema 
 
High functioning.  
Was attending 
college at time of 
death.  Hyperactivity 
from a young age, 
no imitation, special 
ed in early years and 
mainstreamed in 
high school, spoke 
using a script to 
order food in a 
restaurant, repeated 
commercials, only 
spoke about his 
topic of interest, not 
aware of emotions 
of others, 
hypersensitive to 
taste, food, smells 
and light.  
 
 
104
  
UMB4999 
 
20 years 
Male 
14 
hours 
cardiac 
arrhythmia no 
Amoxicillin 
Depakote 
Naltrexone 
Risperdal 
 
severe mental 
retardation, 
aggression, 
compulsion  
 
 
none 
reported 
neuropath; 
normal brain, 
increase in 
leptomengial 
cells of 
meninges and 
gliosis 
Self injurious 
behavior including 
severe head 
banging3, treated 
with   Naltrexone5, 
stereotypy6, 
sensitive GI tract, 
and no 
communication. 
none reported 
Sibling of 
Autistic           
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UMB5378 22 years Male 
8 
hours 
suicide by 
hanging  
Strattera 
(discontinu-
ed before 
death) 
social anxiety 
disorder 
 
 
neuropath; 
normal brain 
without 
neuropath 
findings 
Was a member of a 
set of triplets, one of 
whom was 
diagnosed with 
autism and the 
second had a history 
of depression and 
Asperger-like 
symptoms.   Subject 
was evaluated for 
autism and ADOS 
performed.  Social 
difficulties, lack of 
eye contact, 
grimacing, head and 
leg shaking,  
anxiety, obsessive 
thoughts, difficulties 
completing writing  
assignments due to 
severe self-criticism. 
However, ASD 
diagnosis rejected in 
favor of  social 
anxiety disorder due 
to patient’s history. 
High intelligence; 
very superior verbal 
ability. 
 
Rett            
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UMB4882 17 years  Female 
18 
hours 
complications 
of disorder yes valium 
Rett 
syndrome 
C763T 
nonsense 
mut. hetro. 
cerebral 
palsy 
 
neuropath; 
hypoplasia of 
the brain & 
patchy 
moderate PC  
loss, more 
prominent in 
the folia 
 
Quadriplegic 
cerebral palsy, 
severe scoiliosis, 
hypertonia and 
contracture of 
extremities 
 
UMB1815 18 years Female 
5 
hours 
complications 
of disorder yes  
Tegretol 
Baclofen 
Rett 
syndrome 
Hetro. IVS3-
2A>G 
cerebral 
palsy 
scoliosis 
 
neuropath; 
hypoplasia of 
the brain, 
multifocal 
mal-
development 
contusion to 
the right 
temporal tip 
 
Nonverbal and 
nonambulatory; she 
had crying and 
laughing spells that 
were unprovoked. 
 
UMB4516 20 years Female 
9 
hours natural yes 
Depakene 
Tegretol 
Dilantin 
 
    Rett  
   syndrome 
no genetic 
information. 
Mother had 
10 month 
pregnancy 
complicated 
by influenza 
 
neuropath; 
slight 
cerebral, 
cerebellar and 
nigral 
degeneration 
At 16 months she 
stopped talking, 
engaged in 
stereotyped 
behaviors, ataxia, 
unexpected laughing 
spells. 
 
Angelman           
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UMB1754 4 years Male 
24 
hours drowning yes  
Angelman 
syndrome 
46, XY, del 
(15) 
(q11.2q13) 
 
Some loss of 
cerebral 
cortical 
neurons 
especially in 
layer 3, very 
mild and focal 
loss of 
Purkinje and 
granule cells 
Clinical presentation 
started at 9 months 
and included 
slowing of motor 
and language 
abilities.  He had 
spasticity.  Ataxia 
upper limb and gait.  
Bilateral arachniod 
cysts.  
 
Joubert           
UMB5486 5 years Female 
6 
hours 
complication 
of disorder no 
Ergocal-
ciferol, iron,  
periactin 
Joubert 
syndrome  
Neuropath; 
showed 
hypoplastic 
vermis, 
dilation of 4th 
ventricle, 
“molar tooth 
sign”, grey 
matter 
heterotopia, 
focal white 
matter 
rarefaction. 
 
Dysphagia, fed by 
gastric tube, sleep 
apnea, retinal 
dystrophy, hearing 
impairment,  didn’t 
use arms for 
grasping, 
nephronophthisis, 
kidney failure 
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Table 3 Individuals with autism and neurotypical cases that are in common for the 
microglial density measurements in the cerebellum, frontoinsular cortex and visual 
cortex.  X=microglia density measurements were made for this structure.   
ID GUID Age Sex FI VC  Vermis Lateral Cerebellum 
Autistic        
M4021 NDAR_INVUX206VRV 3a M X X X X 
M4029 NDAR_INVRX268EH4 3b M X X X X 
UMB4671 NDAR_INVVY9 4 F X X X  
UMB4899 NDAR_INVGW538MM3 14b M X X X X 
UMB5278 NDAR_YH540PL 15 F X X X X 
UMB4999 NDAR_INVGW5 20 M  X X X 
Control        
UMB4670 NDAR_INVEA3 4b M X X  X 
UMB5387 not provided 12 M X X X X 
UMB4591 NDAR_INVVH3 16 F X X X X 
UMB4727 NDAR_INVAD6 20b M X X X X 
UMB1542 NDAR_INVXZ7 22a M X X X X 
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Table 4 Purkinje morphometry in individuals with autism and controls.  The Purkinje cells in 
individuals with autism are more round then the controls as shown in the measurements below.
Measurement Definition P value Results
Feret Max 
(µm) Largest dimension of the contour.  0.04311
Control’s Feret max is 
greater than the autistics 
which indicates the 
contour is less round for 
the controls.
Aspect Ratio
The degree of flatness of the contour.  
Aspect ratio approaching 1 indicates a 
rounder contour.
0.02791
Autistic individual’s 
value is closer to 1 which 
indicates the cells are 
rounder.  
Compactness
The relationship between the area and 
maximum diameter.  Compactness for a 
circle is 1.  
0.0415
Autistic individual’s 
value is closer to 1 which 
indicates the cells are 
more compact.  
Shape Factor
The complexity of the contour.  A small 
shape factor is a small perimeter as 
compared to area.  A circle has a small 
shape factor of 3.54.  
0.0347
The autistic individual’s 
have a smaller shape 
factor indicating the 
shape is closer to a circle.  
Form Factor As the contour approaches 1 the shape is approaches a perfect circle.  0.0223
The individuals with 
autism are closer to the 
value of 1 indicating the 
shape is closer to a 
perfect circle.  
Solidity A circle, square or an ellipse has a value of 1.  0.0206
Individuals with autism 
have a greater solidity 
value and are more round. 
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Table 5  Previous Purkinje cell studies in autism.  List of abbreviations:  Autistic=AU Control=CN Mentally Retarded=MR  
Purkinje cell=PC 
Group Cerebellar Region Method Finding 
Williams et 
al. (1980) 
entire cerebellum N=1 AU  Single case confirmed autism.  Tissue was 
formalin fixed paraffin and celloidin embedded blocks, 
cellular and fiber stains.  Qualitative observations.   
 
Qualitative analysis a single case with autism exhibited a decrease 
in number of Purkinje cells.   
Bauman and 
Kemper 
(1985) 
vermis, lateral and 
inferior cerebellar 
hemispheres 
N=1 AU N=1 CN Single autistic case report, celliodin 
blocks and Yakovlev staining protocol.  Qualitative 
observations.   
Qualitative assessment of Purkinje cells.  Described shrinkage and 
fewer Purkinje cells in autistic individual.   
 
Ritvo et al. 
(1986) 
vermis and cerebellar 
hemispheres 
N=4 AU  N= 4 CN Brains were obtained from UCLA 
School of Medicine and all cases met the DSM-III 
criteria for autism, tissue was formalin fixed  and 
sectioned at 10 microns, Nissl stained, coded for 
phenotype.  Linear measurement of Purkinje cells was 
made in 2mm intervals.   
 
Total Purkinje cell counts were significantly reduced in vermis 
and cerebellar hemisphere of each autistic case compared to 
controls in both regions.  
Bauman and 
Kemper 
(1990) 
cerebellum N=1 AU N=2 CN Nissl stained cerebellum.  
Qualitative observations.   
Decrease in Purkinje cells in a single case using a microscopic 
qualitative analysis.   
Bauman et al. 
(1991) 
cerebellum N=5 AU N=4 MR Microscopic and neuroanotomic 
observations of Nissl stained cerebellum.   
Qualitative analysis describing a decrease in Purkinje cell numbers 
in autistics N=5.  N=2 autistics marked PC loss N=3 autistics with 
mild PC loss.    
Fehlow et al. 
(1993) 
cerebellum N=1 AU  N=2 CN Single case report.  Purkinje cell loss in lobules VI and VII. 
Bauman et al. 
(1993) 
cerebellum N=6 AU N=5 MR  DSM III Confirmed autism 
diagnosis, whole brain serial histological sections, 
cerebellar Purkinje cell analysis.  Qualitative 
observations.   
 
Qualitative analysis decrease in Purkinje cell numbers in autistics 
N=6.  N=2 autistics with larger PC size and N=2 autistics with 
smaller PC size.    
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Bailey et al. 
(1998) 
vermis and cerebellar 
hemispheres 
N=6 AU N=7 CN ADI Criteria for autism diagnosis, 
14 microns cut sections, Nissl stained, left and right 
hemispheres stained and hemispheres randomly chosen 
for quantification, Purkinje cells counted as number 
per unit area of the Purkinje cell layer.   
 
Significant decrease in Purkinje cell density in all autistic adults 
compared to the control cases (N=5).   
Fatemi et al. 
(2002) 
cerebellar hemispheres N=5 AU N=5 CN Brains were obtained from Autism 
Research Foundation, investigator blind to phenotype, 
fresh frozen tissue coronal sectioned at 14 microns, 
Nissl stained, linear measurement of  of Purkinje cell 
cross sectional area of 75 randomly chosen Purkinje 
cells using Stereoinvestiagor software.  Total Purkinje 
cell counts per slide were divided by total granule and 
molecular layer areas to obtain granular and molecular 
layer based Purkinje cell densities.   
 
24% decrease in autistic Purkinje cell size.  No difference in 
density Purkinje cell in autistic cases when compared to the 
controls.   
Whitney et al. 
(2008) 
cerebellar hemispheres 
mixed, lobule crus II 
located inferior to the 
horizontal fissure 
N=6 AU N=4 CN Tissue was obtained from Harvard 
Brain Tissue Center, Brain Bank at Duke University 
and University of Maryland Brain Bank.  Formalin 
fixed cerebella, fresh frozen and sectioned at 30 
microns and shrinkage to 7.5 microns, immunostained 
for Calbindin and counterstained with thoinin, Purkinje 
cells quantified in Neurolucida, stereological 
quantification of 10 sections per case counted on 
average 694 PC per brain. 
 
No statistical difference between the number of the Purkinje cells 
in autistic individuals compared to controls.  N=3 autistic cases 
which had decrease PC compared to the mean number of PC in the 
controls.  Whitney et al., (2008) reports that  a subset of 
individuals with autism have a reduction in PCs compared to 
controls.   
Wegiel et al. 
(2013) 
cerebellum N= 12 AU N=10 CN Tissue was obtained from 
NICHD brain and tissue bank, Harvard brain bank and 
brain and tissue bank at New York State Institute. All 
individuals ADIR reported and met criteria for autism. 
Tissue was embedded in celloidin, sectioned at 200 µm 
and Nissl stained. Stereology was used to quantify the 
Purkinje cells. The nuclear radii were used to measure 
the Purkinje sell size. The mean number of Purkinje 
cells examined in the entire cerebellar cortex was 253 
cells per case. 
The average volume of Purkinje cells were significantly (P=0.01) 
reduced by 26% in individuals with autism (N=12) compared to 
controls (N=7).   There was a significant (P=0.001) decrease of 
25%  of Purkinje cells individuals with autism (N=12) compared 
to controls (N=7).   
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X et al. 
(2013) 
lateral cerebellum and 
vermis 
N=10 AU N=9 CN   Tissue obtained from NICHD 
Maryland Brain Bank.  All ADIR confirmed autistic 
cases, sectioned at 50 µm on a viabratome, Nissl 
stained sections, investigator blind to phenotype, linear 
qauntification of PC per mm of entire section (100% 
quantification of PC in PC layer) in Neurolucida 
software, average of 857 PC counted per brain, 100 PC 
per case randomly chosen for shape and size analysis 
using Neurolucida software.   
Significant decrease (P=0.024) in Purkinje cells in cerebellar 
vermis of individuals with autism (N=7).  Purkinje cells are more 
round in several size measures in individuals with autism (N=10) 
compared to controls (N=9) in vermis and lateral cerebellum.   
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Table 6 Confounds were tested for individuals with autism.  Drowning, seizures, medications, 
PMI, brain weight, and age do not account for increase in microglial densities.  In addition, there 
are no correlations with the ADIR and the the microglial counts in the individuals with autism.  
For the Rett’s individuals, there brain size is reduced compared autistics but it does not account 
for the microglial densities when measuring ML total density vs. brain weight (r=0.411 P=0.365 
(ns).  
Confound Molecular Layer Microglial Density 
Drowning 
Autistics that drowned vs. not drowned 
P=0.658 (not significant) 
two tailed t-test 
Seizures 
Autistics that had seizures vs. no seizures 
P=0.507 (not significant) 
two tailed t-test 
Medications 
Autistics that were on medications vs. not 
P=0.161 (not significant) 
two tailed t-test 
Postmortem  
Interval 
(PMI) 
Is PMI correlated with microglial density? 
ML autistics, total density vs. PMI, N=9, Pearson’s  
r=0.344, P=0.182 (ns) 
 
ML controls, total density vs. PMI, N=9, Pearson’s r=-0.197, 
P=0.305(ns) 
Brain Weight 
Is brain weight correlated with microglial density? 
ML autistics, total density vs. BW, N=9, Pearson’s  
r=-0.075, P=0.423(ns) 
 
ML controls, total density vs. BW N=9, Pearson’s r=--0.584, 
P=0.305(ns) 
Age 
Is age correlated with the microglial density? 
ML autistics, total density vs. Age, N=9, Pearson’s r=-0.186, 
P=0.315 (ns) 
ML controls, total density vs. Age, N=9, Pearson’s  
r=-0.090 P=0.408(ns) 
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FIGURES 
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Figure 1 Stereological procedure for quantifying and identifying microglia in control and the brains of individuals with autism; ame method as described 
in Tetreault et al, 2012.  Above is a photomicrograph from the 14 year old autistic male.  
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Figure 2 Method for microglia shape analysis.  For each case, 50 microglia somas were traced using a 100X objective and analyzed for size and shape for 
the molecular layer, and an additional 50, for the granule cell layer.  The cells were randomly chosen using the stereological probe designed for the 
microglial counts.  The measurements for the shape analysis were area, perimeter, Feret maximum, Feret minimum, aspect ratio, compactness, roundness, 
convexity, shape factor, form factor and solidity.  Above is a photomicrograph from the 22 year old autistic male.  
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Figure 3  Linear quantification of the Purkinje cells was measured for each of the cases using Neurolucida software (MBF Bioscience, Williston, VT) and 
the investigators were blind to the case phenotype.  The entire Purkinje cell layer was traced, and 100 percent of the cells were counted in the Purkinje cell 
layer for the section.  The number of Purkinje cells is represented per mm and is calculated by the total number of cells counted in the Purkinje cell layer 
divided by the total length of the Purkinje cell layer for the section.  Above is a photomicrograph from a three year old control male cerebellum taken with 
Nikon Elements Software.  
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Figure 4  Purkinje shape analysis.  The Purkinje cells were traced and analyzed using Neurolucida software (MBF Bioscience, Williston, VT).   For each 
case, 100 Purkinje cells were traced and analyzed for size and shape.  The measurements included area, perimeter, Feret maximum, Feret minimum, aspect 
ratio, compactness, roundness, convexity, shape factor, form factor and solidity.  The average for the 100 cells was taken for each of the measurements for 
each sample.  The means for the groups were measured and analyzed.  Above is a photomicrograph from the 22 year old control male.  
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Figure 5 Average microglial cell counts in FI, VC and cerebellum (GL& ML).  Autistic FI density is 18% greater than controls 
and in VC it is  21% greater than controls (Tetreault et al., 2012).   The density in the cerebellar granule layer shows no significant 
difference between autistic and controls, whereas in the cerebellar molecular layer, individuals with autism have significantly (P 
value is 0.0009, two tailed t-test) greater density of microglia, by 69%.  Error bars represent the standard error of the mean.
(N=10)(N=12) (N=9)(N=11)
P=0.0206 P=0.0002 
(N=9)(N=9) (N=9)(N=9)
P=0.0009
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Figure 6 The individuals with autism (N=9) have significantly (p value is 0.0009, two tailed t-test) greater microglial densities for the cerebellar molecular layer compared to the 
controls (N=9).  The individuals with Rett syndrome (N=3) have significantly greater microglial density in the molecular layer compared to controls (N=9) P < 0.0001.  The cases 
are averaged for the microglial cell counts for vermis and lateral cerebellum since there was no difference in the microglial densities for the two regions.  The  individual with 
Angelman syndrome (N=1) and sibling of an individual with autism (N=1) display microglial densities similar to the individuals with autism for the molecular layer.   The 
individual with Joubert syndrome (N=1) exhibits abnormally low microglial densities for the molecular layer compared to the controls.  Note, the increase in microglial densities is 
specific to the molecular layer where the Purkinje synapses are located.  
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Figure 7  In addition, we found a significant (P=0.042) increase in the soma perimeter of the microglia in individuals with autism (25.8µm) and Rett 
(26.2µm) (P=0.0043) compared to controls (22.2 µm) indicating the microglial cells are activated in the individuals with autism and Rett syndrome.  
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Figure 8 Average Purkinje cells/mm for individuals with autism and controls in lateral cerebellum and cerebellar vermis.  When comparing the vermis of individuals with autism 
and controls there are significantly fewer Purkinje cells in individuals with autism (N=7) compared to controls (N=10) using a two tailed t-test (P value is 0.024) whereas there is 
no difference in lateral cerebellum for the individuals with autism compared to the controls.  In addition, there was a significant (P=0.017) reduction in Purkinje cells in the 
cerebellar vermis compared to lateral cerebellum in the individuals with autism.  Error bars represent the standard error of the mean.  There is no difference for the microglial 
density for the lateral cerebellum when comparing individuals with autism to control.  There is no correlation between the number of Purkinje cells/mm and the microglial 
densities. 
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Figure 9 Purkinje cells/mm for in cerebellar vermis where each data point represents a single case.  There are significantly fewer Purkinje cells in individuals with autism 
(N=7) compared to controls (N=10) using a paired, two tailed t-test (P value is 0.024). The autistic sibling is within the range of the autistic cases for the number of Purkinje 
cells/mm.  Note, the Joubert case is within the control range for Purkinje cells.  
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Type Identification Photomicrograph 
Control CB_CN_2_M_MB1791 
 
 LC_CN_3_F_MB1284 
 
 
126
 CB_CN_4_M_MB4670 
 
 CB_CN_8_F_MB1708 
 
 
127
 LC_CN_12_M_MB5387 
 
 CB_CN_16_F_MB4591 
 
 
128
 CB_CN_16_M_MB5077 
 
 CB_CN_20_M_MB4727 
 
 
129
 LC_CN_20_M_MB4727 
 
 LC_CN_22_M_MB1542 
 
 
130
 CB_CN_22_M_MB1542 
 
Autistic CB_AU_3_M_MB4021 
 
 
131
 LC_AU_3_M_MB4021 
 
 CB_AU_3_M_MB4029 
 
 
132
 LC_AU_3_M_MB4029 
 
 LC_AU_12_M_MB4305 
 
 
133
 LC_AU_14_M_MB4899 
 
 LC_AU_20_M_MB4899 
 
 
134
 LC_AU_20_M_MB4999 
 
Autistic 
Sibling 
BBB: PC_AU_22_M_MB5378 
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 CCC: PC_AU_22_M_MB5378 
 
 LC_AU_22_M_MB5378 
 
 
136
Rett’s 
 
CB_R_20_M_MB4516 
 
 CB_R_18_F_MB1815 
 
 
137
 CB_R_17_F_MB4882 
 
Joubert’s CB_R_17_F_MB4882 
 
 
138
Angelman’s LC_Angel_MB1754 
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Type Identification Photomicrograph 
 
 
 
 
 
 
Control CB_CN_2_M MB1791 vermis 
 
 
CB_CN_3_F MB 1284 vermis 
 
 
140
 CB_CN_16_M MB5077 vermis 
 
 
CB_CN_16_F MB4591 vermis 
 
 
141
 CB_CN_20_M MB4727 vermis 
 
 
CB_CN_22_M MB1542 vermis 
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Autistic 
CB_AU_3_M MB4021 vermis 
 
 
CB_AU_3_M MB4029 vermis 
 
 
143
 CB_AU_4_F MB4671 vermis 
 
 
PC_AU_12_M_4305 vermis 
 
 
144
 CB_AU_14_M MB4899 vermis 
 
 
CB_AU_15_F MB5278 vermis 
 
 
145
 CB_AU_20_M MB 4999 vermis 
 
 
PC_AU_22_M_5378 vermis 
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Rett’s 
CB_R_17_F MB4882 
 
 
CB_R_18_F MB1815 post vermis 
 
 
147
 CB_R_20_M MB4516 
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Autistic
M4021 
M4029 
UMB5308          
UMB4671
UMB797
UMB4305
UMB4899
UMB5278
UMB5294
UMB4999
Sibling of an Autistic
UMB5378
Control
UMB1791
UMB1284
UMB4670
UMB1708
UMB5387
UMB5077
UMB4591
UMB4727
UMB1542
Rett
UMB4882
UMB1815
UMB4516
Angelman
Joubert
Age Brain Weight (g) PMI (h) Purkinje Vermal Cell Counts
Purkinje Lateral 
Cell Counts
Microglia Cell 
Counts ML
Microglial Cell 
Counts GL
3 1330 15 7.865413129 11.73569585 21243.29772 14592.99535
3 1130 13 7.646776501 12.04058681 18358.76686 13435.80712
3 1310 21 No tissue 7.857826801 27429.69403 20848.47471
4 1320 13 6.69408674 No tissue 18788.50962 10807.59115
9 1175 13 No tissue 10.81282991 35886.04286 12289.92183
12 1360 13 9.538720398 9.289495568 22371.15226 16895.44401
14 1450 9 9.516067156 8.609003571 15241.17122 13938.36685
15 1417 13 8.925452442 12.14054967 28988.6059 16090.85909
19 1560 16 No tissue 15.34439645 No tissue  No tissue
20 1427 14 6.636811134 8.053696223 33192.44021 19294.24675
22 1500 8 7.828454321 9.689803795 29764.18009 17967.08225
2 1200 12 10.33585472 No tissue 16856.26353 14013.29603
3 1250 11 10.51957003 15.25332409 16830.20377 11280.74478
4 1470 17 No tissue 8.921328937 8769.916599 15841.43178
8 1320 20 No tissue 8.992850935 12523.84025 14792.30201
12 1750 13 No tissue 9.597261729 11121.02806 15422.21561
16 1330 13 7.401600185 No tissue 14680.23174 16318.56466
16 1330 14 11.22031343 13.22794285 19084.71562 15989.05109
20 1330 5 9.262843321 13.14935218 12552.84258 14025.7618
22 1510 4 8.695774397 11.31411579 14393.23396 17887.83002
17 871 18 9.795804125 No tissue 29008.05413 2755.922427
18 930 5 14.09865894 No tissue 34546.08577 28230.54796
20 980 9 8.42495273 No tissue 25738.40037 17515.97064
4 1360 24 No tissue 9.5712970474828 37263.52756 23700.88462
5 1035 6 12.919871233917 13.810325931048 6168.029371 13403.24101
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Microglia Molecular Layer Area (µm²) Perimeter 
(µm)
Feret Min 
(µm)
Feret Max 
(µm)
Aspect 
Ratio
Compactne
ss
Shape 
Factor
Form 
Factor
Roundness Convexity Solidity Area error 
coeff.
Perimeter 
error coef
Control 
AA:  CB_CN_16_M MB5077
DD: CB_CN_16_M MB5077 
FF:  CB_CN_8_F MB1708 
JJ:  CB_CN_2_M MB1791 
MM:  CB_CN_16_F MB4591 
GGG:  LC_CN_20_M MB4727
III:  LC_CN_22_M MB1542
KKK:  LC_CN_16_F MB4591
NNN:  LC_CN_12_M_MB5387 
RRR:  LC_CN_20_M MB4727
TTT:  LC_CN_3_F MB1284
Autistic 
CC:  CB_AU_9_M MB797 
KK: CB_AU_3_M MB5308 
AAA:  LC_AU_20_M MB4999
EEE:  LC_AU_14_M MB4899
FFF:  LC_AU_12_M MB4305
LLL:  LC_AU_3_M MB4021M
MMM:  LC_AU_15_F MB5278
OOO:  LC_AU_14_M MB4899
PPP:  LC_AU_3_M MB4029M
QQQ:  LC_AU_3_M MB4021M
SSS:  LC_AU_3_M MB4029M  
WWW:  LC_AU_20_M MB4999
Sibling of an Autistic
BBB:  PC_AU_22_M MB5378
CCC:  PC_AU_22_M MB5378
JJJ:  LC_AU_22_M MB5378
Rett 
BB:  CB_R_20_M MB4516 
OO:  CB_R_18_F MB1815 
QQ:  CB_R_17_F MB4882 Sec. 1 vermis
Joubert 
NN:  CB_JS_5_F MB5486 Sec. 10 lat. cerebell. 
PP:  CB_R_17_F MB4882 Sec. 1 vermis
Angelman 
VVV:  LC_Angel_MB1754
Microglia Granule Layer 
Control 
AA:  CB_CN_16_M MB5077
DD: CB_CN_16_M MB5077 
FF:  CB_CN_8_F MB1708 
JJ:  CB_CN_2_M MB1791 
MM:  CB_CN_16_F MB4591 
GGG:  LC_CN_20_M MB4727
III:  LC_CN_22_M MB1542
KKK:  LC_CN_16_F MB4591
NNN:  LC_CN_12_M_MB5387 
RRR:  LC_CN_20_M MB4727
TTT:  LC_CN_3_F MB1284
Autistic
CC:  CB_AU_9_M MB797 
KK: CB_AU_3_M MB5308 
AAA:  LC_AU_20_M MB4999
EEE:  LC_AU_14_M MB4899
FFF:  LC_AU_12_M MB4305
LLL:  LC_AU_3_M MB4021M
MMM:  LC_AU_15_F MB5278
OOO:  LC_AU_14_M MB4899
PPP:  LC_AU_3_M MB4029M
QQQ:  LC_AU_3_M MB4021M
SSS:  LC_AU_3_M MB4029M  
WWW:  LC_AU_20_M MB4999
Rett
BB:  CB_R_20_M MB4516 
OO:  CB_R_18_F MB1815 
QQ:  CB_R_17_F MB4882 Sec. 1 vermis
Sibling of Autistic
BBB:  PC_AU_22_M MB5378
CCC:  PC_AU_22_M MB5378
JJJ:  LC_AU_22_M MB5378
Joubert
NN:  CB_JS_5_F MB5486 Sec. 10 lat. cerebell. 
PP:  CB_R_17_F MB4882 Sec. 1 vermis
Angelman
VVV:  LC_Angel_MB1754
26.6200708 19.5684615 4.96076923 7.13461538 0.81932846 0.70800692 3.81230769 0.86984615 0.67631154 0.98117231 1.00702692 1.43873769 1.49565538
33.8380736 22.2509091 5.56272727 8.14545455 0.81073636 0.69799818 3.84554545 0.85509091 0.66275455 0.98113545 1.00961 1.63585727 1.61507182
25.300212 19.672 4.486 7.582 0.765462 0.627044 3.9356 0.823 0.597238 0.99034 1.004128 1.44635 0.504404
21.8121672 17.5137931 4.48275862 6.42931034 0.81921207 0.70894828 3.78637931 0.87948276 0.67588793 0.99136724 1.00411552 1.28811379 0.43568966
36.9441513 24.6205128 5.46410256 9.5957265 0.7325359 0.60016923 4.05649573 0.77880342 0.54666154 0.98261282 1.03002051 1.81045299 1.87400598
38.2302891 25.2921875 5.446875 9.953125 0.71805313 0.57813281 4.108125 0.76109375 0.52728281 0.98815938 1.02587188 1.85970625 0.65320313
39.7041468 25.8467742 5.46451613 10.2322581 0.71682097 0.57012258 4.11048387 0.76354839 0.52704516 0.98945806 1.03024677 1.90020806 0.63540806
34.4538082 22.2986301 5.73835616 8.19178082 0.81328082 0.71200822 3.81356164 0.86780822 0.66677671 0.98913699 1.00579863 1.63973425 0.53538767
24.1280855 19.5727273 4.36727273 7.51454545 0.74765273 0.60601818 4.02127273 0.79327273 0.56960545 0.98548 1.01644364 1.43884 0.48305818
44.0326687 27.3925373 5.73731343 10.7985075 0.71290448 0.56213582 4.12820896 0.75850746 0.5192597 0.98331493 1.03714776 2.01377463 0.66566567
37.1185414 24.6547486 5.42999768 9.48784186 0.73867664 0.6028804 4.07739599 0.7746927 0.55748381 0.98197558 1.03169359 1.81280721 0.86709121
33.0348717 21.9641509 5.39245283 8.20377358 0.79675283 0.67377264 3.84188679 0.85792453 0.64166132 0.98946792 1.01036792 1.61533679 1.61824151
43.9260441 28.8135593 5.71186441 10.7559322 0.71366271 0.56254407 4.37288136 0.69491525 0.52116102 0.93490169 1.0346339 2.11820169 0.65921525
32.5282152 22.0478261 5.38695652 8.06086957 0.80962609 0.68978043 3.88347826 0.84369565 0.66426304 0.97963261 1.01222609 1.62192174 1.28240435
44.1964854 28.1926829 5.7195122 11.2829268 0.68147805 0.53876829 4.25829268 0.71243902 0.47581707 0.98270976 1.05630244 2.07314878 0.69488049
39.4280885 23.7826923 5.99230769 8.71923077 0.81941731 0.70318462 3.80576923 0.87442308 0.67877692 0.98800192 1.00492885 1.74894808 0.55990192
36.2032036 23.8290909 5.39272727 9.17818182 0.74748727 0.60297636 3.97290909 0.80563636 0.56590364 0.9866 1.01278727 1.75207091 0.58980364
31.7209267 21.36 5.42333333 7.715 0.82854167 0.71746167 3.813 0.872 0.69207167 0.98086 1.00162333 1.57075833 0.51282667
49.6636176 29.3176471 6.09019608 11.5058824 0.70208627 0.55179412 4.18960784 0.73215686 0.50345294 0.98229412 1.05571569 2.15598431 0.73353725
53.9819772 34.0368421 6.50526316 12.7894737 0.66191228 0.5341386 4.64947368 0.62 0.4502614 0.93694737 1.09860526 2.50301579 0.82725439
37.2980373 28.3898305 5.56610169 9.27966102 0.75437627 0.62392373 4.67271186 0.6840678 0.57712034 0.89601017 1.02687288 2.08784576 0.59859153
43.1013475 27.7576271 5.85762712 10.9254237 0.69714407 0.56783898 4.22898305 0.72135593 0.49788136 0.98328814 1.05965763 2.04067966 0.71579661
31.7579121 21.2051724 5.57586207 7.60344828 0.84066207 0.74488966 3.7787931 0.88603448 0.71249828 0.98742241 1.00330345 1.55896207 0.53677241
39.4210128 25.6382979 5.33404255 10.1744681 0.70896809 0.54518511 4.09553191 0.76489362 0.51197872 0.98842766 1.03320213 1.88531915 1.57825745
35.8794929 24.2803571 5.39285714 9.14285714 0.7543125 0.61428214 4.06946429 0.77642857 0.58120893 0.97107679 1.01758214 1.78518571 0.55328036
37.534002 23.696 5.706 8.91 0.786654 0.661478 3.8792 0.8418 0.626216 0.988818 1.011806 1.74224 0.600106
39.3444886 26.3427711 5.4373494 10.2355422 0.69907952 0.55752048 4.26084337 0.71042169 0.4998488 0.97497711 1.0558253 1.93701747 1.67225482
40.651222 25.5381356 5.82372881 9.70338983 0.75461102 0.62405678 4.01822034 0.79279661 0.57932542 0.9770322 1.02622966 1.87757627 1.93842119
38.0762589 26.7933775 5.29470199 10.4788079 0.67388874 0.53268146 4.3913245 0.67509934 0.46520927 0.96865497 1.08319272 1.96998212 1.59371126
56.6219794 36.6990196 6.35686275 14.4333333 0.60338333 0.47313137 4.95068627 0.55803922 0.3783402 0.94826569 1.19015686 2.69859804 2.19809314
41.2520175 32.11 5.29 12 0.62003 0.47599 5.052 0.52375 0.397255 0.9011725 1.1249025 2.3605025 1.6363825
31.7579121 21.2051724 5.57586207 7.60344828 0.84066207 0.74488966 3.7787931 0.88603448 0.71249828 0.98742241 1.00330345 1.55896207 0.53677241
31.0921944 21.8014085 5.20985915 8.00985915 0.79339014 0.6705662 3.93549296 0.82070423 0.63759437 0.97307324 1.01784507 1.60320986 1.60004225
35.1566724 22.9921053 5.59473684 8.39605263 0.80253026 0.68130789 3.89328947 0.83763158 0.65019737 0.97592632 1.00819605 1.69055395 1.39973553
26.5583671 20.2842105 4.57236842 7.82236842 0.75861974 0.61729342 3.95697368 0.81276316 0.58591447 0.98966316 1.01214868 1.49065132 0.54752632
26.7032456 20.2736842 4.61754386 7.77368421 0.75947193 0.61626842 3.95333333 0.81649123 0.58734211 0.98707018 1.01200702 1.4909 0.52258772
40.8455079 27.6634921 5.7015873 10.552381 0.69965873 0.5668746 4.32984127 0.69285714 0.49959683 0.95708254 1.065511111 2.03369683 1.70582698
38.0869813 26.1770833 5.37291667 10.3770833 0.68264792 0.54042708 4.266875 0.70791667 0.47618333 0.98221875 1.06402292 1.92495833 0.69781667
40.2231725 26.9627451 5.40980392 10.727451 0.67940392 0.53352549 4.27882353 0.70039216 0.47097059 0.98601373 1.06015882 1.98214314 0.6824098
38.4742439 24.8298246 5.45789474 9.75263158 0.72674912 0.57768246 4.01912281 0.78666667 0.53581579 0.98887018 1.01780877 1.82555088 0.61428246
47.0563909 30.6309091 5.72727273 12.32 0.63905818 0.48904 4.49890909 0.644 0.41802182 0.96983273 1.09887091 2.25226 0.75690727
41.9709967 27.9733333 5.67833333 10.9116667 0.68521333 0.54556167 4.32016667 0.69566667 0.47901167 0.97074667 1.06294833 2.05696667 0.69659333
42.920982 28.3945252 5.7683868 10.7930583 0.70114931 0.56731045 4.35499637 0.69983144 0.50465863 0.95974839 1.06482088 2.08638508 1.08307919
37.2453423 24.228866 5.55773196 9.22680412 0.75380412 0.62415361 3.99989691 0.79731959 0.57676495 0.9842268 1.02587113 1.78136082 1.4809299
53.6573574 33.0333333 6.62777778 11.8814815 0.7090111110.581961111 4.51148148 0.66407407 0.51219074 0.92855185 1.05415741 2.42901481 0.72835
31.0921944 21.8014085 5.20985915 8.00985915 0.79339014 0.6705662 3.93549296 0.82070423 0.63759437 0.97307324 1.01784507 1.60320986 1.60004225
33.3298381 25.1452381 4.90238095 9.98809524 0.66714048 0.5205619 4.39166667 0.6752381 0.4580619 0.97573095 1.08445714 1.84889286 0.64972381
43.3136262 27.6 5.85714286 10.7642857 0.70708095 0.57562143 4.20595238 0.72952381 0.51046905 0.98314286 1.06478571 2.02927143 0.66680238
37.8083462 24.7788462 5.43846154 9.70384615 0.72616346 0.58287115 4.04826923 0.77788462 0.53630577 0.98656538 1.02253269 1.82223077 0.60158654
37.5569585 24.6075472 5.54150943 9.47924528 0.73534717 0.60398113 4.05339623 0.77849057 0.54943585 0.98535283 1.03138679 1.80941887 0.60777547
51.3329667 32.8912281 6.14561404 13.1087719 0.62350702 0.48657719 4.61912281 0.60070175 0.39504561 0.96195088 1.11779825 2.4181386 0.86735614
47.50085 29.9160714 6.24642857 11.1589286 0.7017125 0.57769286 4.38571429 0.67410714 0.50025714 0.94682857 1.07083036 2.19975179 0.74875536
43.608549 31.054902 5.88823529 10.7666667 0.70365294 0.57352745 4.75058824 0.60568627 0.5062 0.88977843 1.06269608 2.28335686 0.69225294
32.5577681 22.89375 5.22291667 8.75416667 0.73097917 0.6151125 3.94 0.76958333 0.55370833 0.98785625 1.01098333 1.64254583 0.61892292
32.732631 22.6603448 5.03965517 8.8362069 0.73891207 0.58908621 3.97827586 0.80206897 0.55238276 0.99032414 1.01546379 1.66646379 0.5664931
42.5280317 26.7698413 5.99047619 10.0333333 0.73834603 0.61385556 4.13444444 0.74603175 0.55119048 0.96766032 1.03942698 1.96832222 1.58812381
46.5067188 28.2630435 6.0942029 10.8971014 0.71625435 0.57922754 4.16594203 0.74014493 0.52152464 0.97784638 1.05837681 2.07820145 1.89535072
44.9542295 29.9965909 5.68295455 11.9295455 0.64132045 0.50360114 4.55340909 0.63159091 0.42337841 0.972325 1.10951477 2.20545 1.72624886
42.3330807 26.0526316 5.81578947 10.0280702 0.74231404 0.59954386 4.02035088 0.79122807 0.56052456 0.98925789 1.03095263 1.91552281 0.74889298
44.6929102 27.6142857 5.91632653 10.7285714 0.71515918 0.57134694 4.14387755 0.74571429 0.52084286 0.97787551 1.02868367 2.03096122 0.69110816
41.6390173 26.9038462 5.74615385 10.5076923 0.69885 0.56297692 4.20230769 0.72692308 0.49676154 0.98468077 1.05689231 1.978 0.67796154
53.7309788 35.5020202 6.25858586 13.6424242 0.61728687 0.48592323 4.90565657 0.55373737 0.39283131 0.93671919 1.17044747 2.61017071 2.33090606
47.50085 29.9160714 6.24642857 11.1589286 0.7017125 0.57769286 4.38571429 0.67410714 0.50025714 0.94682857 1.07083036 2.19975179 0.74875536
34.1859373 23.1149254 5.29701493 8.79850746 0.75351642 0.62360597 4.00358209 0.79358209 0.57677463 0.98178955 1.01515522 1.69995672 0.58233881
 
150
Contour Name
Control Vermis
Area (µm≤) Perimeter 
(µm)
Detected 
Objects
Feret Min 
(µm)
Feret Max 
(µm)
Aspect Ratio Compactness Object 
Markers
Shape Factor Form Factor Roundness Convexity Solidity Area error 
coeff.
Perimeter 
error coef
1: CB_CN_22_M MB1542 vermis
2: CB_CN_3_F MB 1284 vermis
7: CB_CN_16_F MB4591 vermis
10: CB_CN_20_M MB4727 vermis
AA: CB_(CN)_16_M MB5077 vermis
CC:  CB_CN_2_M MB1791 vermis
EE:  CB_CN_16_F MB4591 vermis
JJ:  CB_CN_16_M MB5077 vermis
PPP: CB_CN_16_M MB5077 vermis
KK:  CB_CN_2_M MB1791 vermis
UUU:  CB_CN_16_F MB4591 post vermis
RRR:  CB_CN_2_M_MB1791 vermis
Control Lateral Cerebellum
4: CB_CN_4_M MB4670 lateral
BBB:  LC_CN_12_M_MB5387
CCC:  LC_CN_16_F_4591 lateral
EEE:  LC_CN_22_M_1542 lateral
GGG:  LC_CN_20_M_4727 lateral
II:  CB_CN_8_F MB1708 lateral
KKK:  LC_CN_3_F MB1284 lateral
AAA2:  CB_CN_8_F MB1708 lateral
Autistic Vermis
3: CB_AU_20_M MB 4999 vermis
5: CB_AU_4_F MB4671 vermis
6: CB_AU_3_M MB4021 vermis 
8: CB_AU_3_M MB4029 vermis
9: CB_AU_15_F MB5278 vermis
11: CB_AU_14_M MB4899 vermis
HHH:  PC_AU_12_M_4305 vermis
Autistic Lateral Cerebellum
CCC2:  LC_ASD_19_M_MB5294 lateral
FFF:  LC_AU_15_F_5278 lateral
III:  LC_AU_14_M 4899 lateral
JJJ:  LC_AU_12_M_4305 lateral
LLL:  LC_AU_3_M_M4029M lateral
MMM:  LC_AU_20_M_4999 lateral
XXX:  CB_AU_3_M_MB5308 Nissl lat. cereb.
ZZZ:  CB_AU_9_M MB797 generic cereb.
DD:  CB_AU_3_M MB5308 lateral
GG:  CB_AU_9_M MB797 generic cerebellum
LL:  CB_AU_9_M MB797 generic 
NNN:  LC_AU_3_M_M4021M lateral
Sibling of Autistic
AAA:  PC_AU_22_M_5378 vermis 
DDD:  LC_AU_22_M_5378 lateral
Rett Vermis
SSS:  CB_R_17_F MB4882 post vermis
TTT:  CB_R_20_M MB4516 post vermis
WWW:  CB_R_18_F MB1815 post vermis
YYY:  CB_R_17_F MB4882 Nissl post vermis
BB:  CB_R_17_F MB4882
FF:  CB_R_18_F MB1815
MM:  CB_R_20_M MB4516
Joubert
QQQ:  CB_JS_5_F MB5486 Lat
VVV:  CB_JS_5_F MB5486 vermis
Angelman
BBB2:  LC_Angel_MB1754
584.58066667 99.78172043 0 22.450537634 38.501075269 0.7154129032 0.6005655914 0 4.1638709677 0.7366666667 0.5204408602 0.9825677419 0.9527301075 18.342715054
645.50380172 100.52931034 0 23.499137931 38.294827586 0.75835 0.6346301724 0 3.9818103448 0.8037068966 0.584725 0.9874931034 0.9765362069 18.479143966
614.77498261 99.753913043 0 21.935652174 38.907826087 0.7277591304 0.5843156522 0 4.0493913043 0.7747826087 0.538126087 0.9869895652 0.9745617391 18.337304348 3.6757434783
782.875 113.12333333 0 24.023333333 45.238888889 0.7020555556 0.5442833333 0 4.077 0.7644444444 0.50037111111 0.99105 0.98045111111 20.793742222 3.5850666667
672.88085217 102.23534483 0 22.957758621 39.928448276 0.7306215517 0.5908905172 0 3.9486206897 0.7935344828 0.5467318966 0.9945146552 0.9768732759 18.642396552 3.0389672414
581.8710084 101.21932773 0 19.544537815 41.851260504 0.6606840336 0.4922663866 0 4.2493277311 0.7135294118 0.4483294118 0.9918596639 0.9747571429 18.606162185 3.3634848739
800.60685586 109.55675676 0 26.803603604 40.627927928 0.7900198198 0.6738954955 0 3.8997297297 0.832972973 0.631536036 0.9860099099 0.9840891892 20.139478378 3.6281234234
678.79601626 100.20081301 0 24.443902439 37.657723577 0.7792642276 0.657899187 0 3.8896747967 0.836504065 0.614695122 0.9936121951 0.9842398374 18.418996748 4.3753203252
573.23704854 91.361165049 0 21.818446602 35.144660194 0.7688330097 0.6328990291 0 3.8633009709 0.8477669903 0.5992067961 0.9951747573 0.991776699 16.79302233 4.6941417476
602.80033594 99.265625 0 20.95625 39.84140625 0.6960445313 0.5420992188 0 4.0975 0.7559375 0.4909789063 0.9925 0.9718820313 18.247907813 4.0386085938
555.09581915 89.889361702 0 22.091489362 33.742553191 0.78905 0.6672829787 0 3.8532978723 0.850212766 0.6296606383 0.9920989362 0.9885712766 16.524023404 5.6679234043
529.80555556 92.762037037 0 18.930555556 38.143518519 0.6811527778 0.5068546296 0 4.0890740741 0.7615740741 0.4718925926 0.9956796296 0.9869777778 17.051913889 4.9690555556
691.25585833 104.94166667 0 23.916666667 40.2125 0.7419475 0.6117691667 0 4.04125 0.7819166667 0.5602266667 0.98324 0.9741066667 19.2907875
674.902 101.95263158 0 21.913684211 40.750526316 0.7220715789 0.5508705263 0 3.9542105263 0.8102105263 0.5268684211 0.9950989474 0.9896210526 18.741411579 5.3251778947
670.97844444 97.9111111111 0 23.6 37.725252525 0.7765030303 0.6360555556 0 3.8073737374 0.8705050505 0.6085464646 0.9975959596 0.997330303 17.998634343 2.2876525253
622.86252632 97.390526316 0 21.504210526 37.986315789 0.7437926316 0.5757926316 0 3.9213684211 0.82 0.5575884211 0.9909989474 0.9896863158 17.902696842 5.1809210526
775.95897368 107.98947368 0 24.085087719 42.19122807 0.7511078947 0.5868552632 0 3.8953508772 0.8333333333 0.5703394737 0.9953008772 0.9896666667 19.851285088 5.6604649123
929.60593878 120.17346939 0 28.214285714 45.669387755 0.758344898 0.6320367347 0 3.9639795918 0.8051020408 0.5818663265 0.9897428571 0.9709989796 22.090744898 5.3764346939
727.68475758 104.6 0 23.117171717 41.777777778 0.7288272727 0.5601282828 0 3.9029292929 0.8285858586 0.5347131313 0.9942767677 0.9922929293 19.228033333 5.5713676768
648.88502586 101.11206897 0 22.18362069 39.907758621 0.7265258621 0.5734293103 0 4.0020689655 0.7929310345 0.5368224138 0.9962741379 0.986762931 18.586515517 2.4486448276
802.87467778 113.06666667 0 26.018888889 43.393333333 0.7483922222 0.62043 0 4.0073333333 0.79211111111 0.57046 0.9873477778 0.9817055556 20.78461
624.83116935 106.03467742 0 20.081451613 43.857258065 0.6611717742 0.4864532258 0 4.2637096774 0.7125 0.450966129 0.9928524194 0.9766443548 19.491295161 3.6670282258
868.99047619 113.22095238 0 27.847619048 42.219047619 0.7890152381 0.6706942857 0 3.876 0.8420952381 0.6295495238 0.9902247619 0.9867733333 20.812666667 3.9614838095
614.77498261 99.753913043 0 21.935652174 38.907826087 0.7277591304 0.5843156522 0 4.0493913043 0.7747826087 0.538126087 0.9869895652 0.9745617391 18.337304348 3.6757434783
488.16476531 86.880612245 0 20.287755102 33.717346939 0.7467112245 0.6194346939 0 3.9541836735 0.81 0.5647816327 0.9917469388 0.9856632653 15.970661224 3.2507969388
992.39010989 119.0010989 0 30.010989011 44.195604396 0.8044043956 0.6872912088 0 3.8036263736 0.871978022 0.6514967033 0.991510989 0.9931967033 21.875143956 3.9035263736
593.44978378 95.847747748 0 21.182882883 37.731531532 0.7354675676 0.5768882883 0 3.9487387387 0.8115315315 0.5474972973 0.9922873874 0.9898009009 17.618954955 4.9224756757
670.97844444 97.9111111111 0 23.6 37.725252525 0.7765030303 0.6360555556 0 3.8073737374 0.8705050505 0.6085464646 0.9975959596 0.997330303 17.998634343 2.2876525253
429.26195833 78.988541667 0 18.995833333 30.209375 0.777621875 0.6413416667 0 3.8339583333 0.859375 0.6104010417 0.996546875 0.99105625 14.520882292 4.6846385417
734.97954545 104.44363636 0 23.661818182 40.651818182 0.7580245455 0.5981472727 0 3.8736363636 0.8421818182 0.5811145455 0.9952454545 0.9923545455 19.199851818 5.5576254545
643.44780808 97.378787879 0 22.990909091 37.609090909 0.7669757576 0.6277616162 0 3.8597979798 0.8488888889 0.5948787879 0.9956292929 0.9892272727 17.900765657 4.6346717172
517.00266667 88.272916667 0 20.448958333 33.866666667 0.7613197917 0.6162010417 0 3.9067708333 0.8288541667 0.5865645833 0.9939239583 0.9848635417 16.226722917 4.9658177083
647.97445263 95.595789474 0 23.676842105 35.829473684 0.8031536842 0.6728715789 0 3.7847368421 0.8807368421 0.6507242105 0.9949873684 0.9908357895 17.571730526 5.8256810526
570.178 92.169902913 0 20.866990291 36.346601942 0.7414436893 0.586568932 0 3.9024271845 0.8288349515 0.5553582524 0.9980834951 0.9948126214 16.94346699 1.9749262136
437.62831858 78.340707965 0 19.913274336 29.238938053 0.8096362832 0.6910858407 0 3.762920354 0.8904424779 0.6608141593 0.9983787611 0.9972327434 14.400631858 1.9539061947
646.87280702 101.65789474 0 21.731578947 40.189473684 0.7124859649 0.5522429825 0 4.0622807018 0.7706140351 0.5160017544 0.9913070175 0.9787754386 18.68692807 3.3895947368
672.71721705 100.08062016 0 24.034108527 38.407751938 0.7681224806 0.6391062016 0 3.8733333333 0.8413953488 0.5959953488 0.9915767442 0.989348062 18.396582946 4.2134426357
772.89516807 109.90588235 0 24.901680672 42.905882353 0.7349529412 0.5923941176 0 3.983697479 0.7984033613 0.547312605 0.9940865546 0.9838352941 20.203836134 3.9874865546
526.85 88.371 0 21.849 33.04 0.782778 0.667068 0 3.882 0.8388 0.61856 0.99414 0.981647 16.245501 4.68154
473.24011458 82.810416667 0 20.128125 31.263541667 0.7850458333 0.6576885417 0 3.8552083333 0.8522916667 0.6245677083 0.9920072917 0.9891770833 15.221547917 5.787434375
494.03846154 83.175 0 21.734615385 30.378846154 0.8271278846 0.7238403846 0 3.7596153846 0.8911538462 0.6887432692 0.9939721154 0.9919855769 15.288986538 5.1074913462
622.24519231 96.366346154 0 22.468269231 37.170192308 0.7583009615 0.6164538462 0 3.9081730769 0.8296153846 0.5836644231 0.9946894231 0.9895682692 17.714075 5.1314740385
423.17773267 79.721782178 0 18.514851485 30.707920792 0.7582217822 0.6150633663 0 3.9126732673 0.8272277228 0.5832831683 0.9928594059 0.9875227723 14.655058416 4.349890099
437.62831858 78.340707965 0 19.913274336 29.238938053 0.8096362832 0.6910858407 0 3.762920354 0.8904424779 0.6608141593 0.9983787611 0.9972327434 14.400631858 1.9539061947
540.53040909 87.912727273 0 22.712727273 32.088181818 0.82045 0.7171181818 0 3.7960909091 0.8747272727 0.6781618182 0.9909381818 0.9906318182 16.16125 4.0926136364
553.09177477 92.364864865 0 21.454954955 35.354954955 0.7519261261 0.6179108108 0 3.9665765766 0.804954955 0.5725126126 0.9919603604 0.9754693694 16.978851351 4.1211720721
778.27823894 109.18230088 0 25.118584071 42.531858407 0.7456566372 0.6048238938 0 3.9337168142 0.8168141593 0.5626743363 0.9916371681 0.9883973451 20.069947788 4.3414123894
348.12870588 76.370588235 0 14.823529412 31.610784314 0.6711980392 0.4822264706 0 4.1164705882 0.7491176471 0.4566490196 0.9941647059 0.9871215686 14.038301961 4.5443
383.40694231 78.261538462 0 16.721153846 31.225961538 0.7197605769 0.5596019231 0 4.0158653846 0.7906730769 0.5280355769 0.9928432692 0.9851201923 14.386275 5.0393009615
604.04120755 96.596226415 0 21.578301887 38.069811321 0.7347415094 0.5860179245 0 3.9672641509 0.8068867925 0.5487858491 0.9930169811 0.9856075472 17.757011321 6.5764009434
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